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EAST AND SOUTH-EAST ASIA AND OCEANIA IN A GLOBAL CONTEXT
1
This report analyses recent trends and developments of 
the synthetic drugs market in East and South-East Asia 
and Oceania, comprising both amphetamine-type stim-
ulants (ATS) and new psychoactive substances (NPS). 
NPS are substances of abuse that are not controlled by 
the International Drug Conventions but which may 
pose a public health threat. In this context, the term 
‘new’ does not necessarily refer to new inventions but 
to substances that have recently become available.1 East 
and South-East Asia and Oceania has the largest ATS 
market in the world and in recent years the scope and 
availability of NPS has rapidly expanded. Moreover, 
this synthetic drugs market is becoming more complex 
and interconnected with other regions. These develop-
ments warrant an in-depth study to understand the 
current threat and impact of ATS and NPS in East and 
South-East Asia and Oceania within a global context. 
The analysis of the synthetic drug problem in the re-
gion is essential to complement the understanding of 
the illicit market for synthetic drugs called for in the 
2009 Political Declaration and Plan of Action on Inter-
national Cooperation towards an Integrated and Bal-
anced Strategy to Counter the World Drug Problem. 
 
The availability of quality data and information-sharing 
in the region has improved with the support of the Drug 
Abuse Information Network for Asia and the Pacific 
(DAINAP), which offers a regional control mechanism 
for drug monitoring.2 However, the quality of data and 
information on some aspects of the synthetic drugs mar-
ket remains limited. Particularly, demand-related data 
on the extent and pattern of use, and treatment remains 
scarce. And yet, methamphetamine and other synthetic 
drugs that pose a serious health threat to users seem to 
become increasingly available and are a challenge for 
health care providers and drug control authorities.
Challenges in reducing the supply and demand 
for synthetic drugs
Methamphetamine continues to dominate the syn-
thetic drugs market in East and South-East Asia and 
is mainly available in two forms: methamphetamine 
tablets and crystalline methamphetamine. Increasing 
methamphetamine seizures and expert perception of 
high levels of methamphetamine tablet and crystalline 
methamphetamine use indicate the presence of a large 
and possibly expanding market in East and South-East 
Asia.3 For some years, the “ecstasy”4 market has been 
concentrated in parts of Oceania. Recently, according 
to expert perception, there is an emerging “ecstasy” 
market in parts of East and South-East Asia with use 
reported in Indonesia and countries in the Mekong 
sub-region.5
Addressing the trafficking of synthetic drugs in East and 
South-East Asia involves a number of difficulties. Over 
the last several years, countries in East and South-East 
Asia and Oceania have experienced rapid economic ex-
pansion. For instance, the share of the regions’ global 
Gross Domestic Product (GDP) based on purchasing-
power-parity (PPP), is estimated to have increased 
from about 10 per cent in 2000 to over 30 per cent in 
2014 at a value of more than US$ 28 trillion.6 Except 
for a sharp drop in 2009, exports and imports to and 
from countries in East and South-East Asia and Ocea-
nia have also significantly increased over the years. Be-
tween 2002 and 2013, imports and exports more than 
tripled to more than US$ 6.5 trillion and 6.9 US$ 
trillion respectively.7 Under these conditions of rapid 
1. East and South-East Asia and 
Oceania in a global context
1  For recent decisions of  the Commission on Narcotic Drugs related 
to the international scheduling of  some NPS, see United Nations, 
Commission on Narcotic Drugs, Report on the fifty-eight session, 5 
December 2014 and 9 to 17 March 2015. E/CN.7/2015/15. 
2  DAINAP is supported by UNODC’s Global SMART (Synthetics 
Monitoring: Analyses, Reporting and Trends) Programme which is 
working with partner countries in the region since 2008.
3  Drug Abuse Information Network for Asia and the Pacific (DAIN-
AP).
4          “Ecstasy” pills sold as ecstasy in East and South-East Asia may con-
tain substances other than MDMA.  
5  For a more detailed analysis of  “ecstasy” use in East and South-East 
Asia and Oceania, see chapter titled “A growing presence of  ecstasy” 
of  this report.
6  Calculations based on figures derived from the International Mon-
etary Fund (IMF), World Economic Outlook Database, April 2014.
7  Calculations based on figures derived from the United Nations Con-
ference on Trade and Development (UNCTAD) Statistics, 2013.
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expansion of licit trade flows, it is not unlikely that op-
portunities for misusing the licit trade for illicit purpos-
es have also increased and are being exploited. While 
in this context many positive economic opportunities 
opened up, challenges for governments in their efforts 
to tackle the problem of synthetic drugs evolved as well. 
A large and expanding market for synthetic 
drugs
East and South-East Asia and Oceania is estimated to 
have the largest market for ATS users in the world. Ac-
cording to the United Nations Office on Drugs and 
Crime (UNODC) estimates for 2012, East and South-
East Asia and Oceania together have the largest number 
of ATS (excluding “ecstasy”) users worldwide at almost 
9.5 million users, as well as the largest number of “ec-
stasy” users at 3.9 million. In Oceania, the estimated 
annual prevalence rates for both ATS (excluding “ecsta-
sy”) use and “ecstasy” use for 2012 were the highest in 
the world at 2.1 per cent and 2.9 per cent respectively.8 
 
Moreover, ATS seizures reported in the region have 
accounted for an increasing share of global seizures 
and since 2010 have reported the second largest 
amount relative to other regions of the world. In East 
and South-East Asia and Oceania, ATS seizures have 
increased from almost 12 tons in 2008 to about 48 
tons in 2013. This significant increase of seizures in 
the region might partly be the result of effective law 
enforcement measures, but also points to expanding 
manufacture and an increase of trafficking to and 
through the region. Since 2011, seizures in the re-
gion have annually exceeded those reported in Africa 
and Europe as well as those reported in other parts 
of Asia although the largest amount of ATS seizures 
worldwide has been reported in the Americas (primar-
ily North America) since 2009. However, seizures in 
the Americas have decreased in recent years, drop-
ping from up to 81 tons in 2011 to 49 tons in 2013, 
only somewhat higher than the amount reported in 
East and South-East Asia and Oceania that year. 
Between 2009 and 2013, a growing number of coun-
tries worldwide have identified countries in East and 
South-East Asia and Oceania as destinations for seized 
ATS.9 Given that the exact annual amount of seized 
ATS destined for countries in this region is unknown, 
the trend does not necessarily imply that increasing 
amounts of seized ATS are destined for countries in 
the region, but that the interception of trafficking at-
tempts to East and South-East Asian countries has in-
creased. Among the 95 countries and territories world-
wide identified as destination for ATS seized between 
2009 and 2013, three out of the five most frequently 
mentioned ones were located in East and South-East 
Asia and Oceania, specifically Australia, Japan and 
Malaysia, the other two countries being the Russian 
Federation and the United Kingdom.10 Moreover, Ma-
laysia was the most frequently reported destination for 
intercepted ATS trafficking attempts in the world in 
2012.11
Figure 1. ATS seizures reported worldwide, by 
region, 2008-2013
Source(s): United Nations Office on Drugs and Crime (UNODC), 
Annual Report Questionnaire 2008-2013.
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Figure 2. ATS seizures reported in East and 
South-East Asia and Oceania, 2008-2013
Source(s): United Nations Office on Drugs and Crime (UNODC), 
Annual Report Questionnaire 2008-2013.
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8  United Nations Office on Drugs and Crime (UNODC), World Drug 
Report 2014, New York, June 2014.
9  United Nations Office on Drugs and Crime (UNODC), Annual Re-
port Questionnaire 2009-2013.
10  United Nations Office on Drugs and Crime (UNODC), Annual Re-
port Questionnaire 2009-2013.
11  United Nations Office on Drugs and Crime (UNODC), Annual Re-
port Questionnaire 2012.
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The rapid rise of ATS seizures reported in East and 
South-East Asia and Oceania is primarily attributable to 
the increase of methamphetamine seizures which almost 
quadrupled from about 11 tons in 2008 to almost 42 
tons in 2013. Over the same period, “ecstasy” seizures 
reported in the region have annually remained below 1 
ton, with the exception of 2012, when “ecstasy” seizures 
increased to about 2 tons. Amphetamine seizures re-
ported in the region have also remained below 1 ton for 
some years, but have risen to more than 2 tons in 2011 
and 2013. On the whole, amphetamine and “ecstasy” 
together, have annually accounted for a small share 
of ATS seizures reported in East and South-East Asia, 
whereas methamphetamine has annually accounted for 
more than 85 per cent of ATS seizures reported in the 
region since 2008.
Diversification of the synthetic drugs market
There is a large and growing market for methamphet-
amine in East and South-East Asia. In the region, meth-
amphetamine is predominantly available in two forms: 
methamphetamine tablets and crystalline methamphet-
amine. Methamphetamine tablets, commonly known as 
‘yaba’ in the region, are small pills typically of low purity 
which are available in many different shapes and co-
lours. Crystalline methamphetamine, also called ‘crystal 
meth’, ‘ice’ or ‘shabu’, is usually of much higher purity 
than the tablet form.12 These two forms of metham-
phetamine portray different trends in their geographic 
spread and trafficking routes.13 Methamphetamine tab-
lets are mainly manufactured in the Mekong sub-region 
of East and South-East Asia and seizure reports indicate 
that such tablets are mostly intended for markets within 
this sub-region. However, there have recently also been 
some indications of an emerging market for metham-
phetamine tablets in the Republic of Korea, Malaysia 
and Singapore.14 Unlike with methamphetamine tab-
lets, crystalline methamphetamine has become a geo-
graphically wide-spread drug trafficked across East and 
South-East Asia.15 Although crystalline methamphet-
amine continues to be manufactured within the region 
on a large scale16, a complex international trafficking 
pattern of crystalline methamphetamine has evolved in 
recent years, originating from Western Africa, Western 
Asia, North America, and, more recently, South Asia.17
As in many other parts of the world, the synthetic drugs 
market in East and South-East Asia and Oceania has 
become increasingly diversified with the rapid emergence 
of a growing number of NPS18 that are designed to mimic 
the effects of substances under international control. 
Although the total number of NPS in the region has 
fluctuated over the years, reports on the emergence of 
NPS in the region have increased from 34 substances in 
2009 to a total of 137 substances by November 2014.19 
Certain NPS, such as ketamine and kratom, have had a 
long established market in several countries of the region 
while others seem to be transient. Of the 137 NPS that 
have been reported to have emerged, 36 NPS (mostly 
synthetic cannabinoids and synthetic cathinones) have 
disappeared from the market since 2008.20 Moreover, 
data on NPS emergence suggests that some countries, 
such as Australia, Indonesia, Japan, New Zealand and 
Singapore, have a more diversified NPS market than 
other countries in the region. However, the capacity of 
forensic laboratories to identify NPS differs between 
countries in the region and it is likely that this has an 
influence on how many NPS have been reported.21
12  For more information on crystalline methamphetamine purity, see 
chapter titled “A diversified market for methamphetamine in East and 
South-East Asia” of  this report.
13  For regional analysis of  methamphetamine tablet and crystalline 
methamphetamine markets in East and South-East Asia, see chapter 
titled “A diversified market for methamphetamine in East and South-
East Asia” of  this report.
14  For more information on the methamphetamine tablet market in 
East and South-East Asia, see chapter titled “A diversified market for 
methamphetamine in East and South-East Asia” of  this report.
15  Drug Abuse Information Network for Asia and the Pacific (DAIN-
AP); United Nations Office on Drugs and Crime (UNODC), Annual 
Reports Questionnaire 2009-2013.
16  China National Narcotics Control Commission (NNCC), Ministry of  
Public Security, “China country presentation”, presented at the Global 
SMART Programme regional meeting, Yangon, Myanmar, 20-21 Au-
gust 2014; National Anti-Drugs Agency of  Malaysia (NADA) and the 
Royal Malaysia Police (RMP), “Malaysia country report”, presented at the 
Global SMART Programme regional meeting, Yangon, Myanmar, 20-21 
August 2014; United Nations Office on Drugs and Crime (UNODC), 
Annual Reports Questionnaire 2009-2013.
17  United Nations Office on Drugs and Crime (UNODC), 2014 Global 
Synthetic Drugs Assessment: Amphetamine-type stimulants and new psychoactive 
substances, Vienna, May 2014; International Safety and Security Coopera-
tion Division, Ministry of  Foreign Affairs (MOFA), Japan, “Japan coun-
try presentation”, presented at the Global SMART Programme regional 
meeting, Yangon, Myanmar, 20-21 August 2014; Royal Malaysian Police 
(RMP) and National Anti-Drugs Agency (NADA), “Malaysia country 
presentation”, presented at the Global SMART Programme regional 
meeting, Yangon, Myanmar, 20-21 August 2014; Office of  Narcotics 
Control Board (ONCB), “Thailand country presentation”, presented at 
the Global SMART Programme regional meeting, Yangon, Myanmar, 20-
21 August 2014.
18  For the purpose of  this report, the analysis of  NPS includes ketamine 
which differs from other NPS in that is widely used in human and veteri-
nary medicine, while most NPS have little or no history of  medical use. 
19  United Nations Office on Drugs and Crime (UNODC), Early Warning 
Advisory (EWA). Accessed in November 2014 at www.unodc.org/LSS/
Home/NPS.
20  United Nations Office on Drugs and Crime (UNODC), Early Warning 
Advisory (EWA). Accessed in November 2014 at www.unodc.org/LSS/
Home/NPS.
21  For an in-depth analysis of  the NPS market in East and South-East Asia, 
see chapter titled “The NPS market in East and South-East Asia and 
Oceania” of  this report.
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So far, it remains unclear whether there is a link between 
the growing availability of NPS and the “ecstasy” 
market. However, evidence from New Zealand points 
to the existence of a two-pronged market in which 
“ecstasy” high in MDMA is being supplied from 
countries outside the region, predominantly Western 
Europe, and “ecstasy” containing various controlled 
and non-controlled substances is being manufactured 
within the region.22 In East and South-East Asia and 
Oceania, there are reports of seized “ecstasy” tablets 
that have been found to contain little or no MDMA 
and consist mainly of a blend of non-controlled 
substances including NPS.23 Overall, it remains 
unclear whether certain NPS are replacing MDMA, 
in either the short or long term, or whether they are 
simply being used to supplement the “ecstasy” market. 
The large amount of ecstasy chemical precursors 
seized in recent years in East and South-East Asia and 
Oceania indicates the potential for significant ecstasy 
manufacture. Moreover, “ecstasy” seizure data suggests 
that the region accounts for an increasing share of the 
global “ecstasy” market.24 
International efforts for an integrated response
The synthetic drugs market in East and South-East 
Asia and Oceania is not a separate and self-contained 
entity, but part of a larger complex global network with 
interconnected channels for the supply and demand of 
synthetic drugs. Therefore, information exchange and 
cooperation on national, regional and international 
levels is crucial to establish an effective response to 
the growing problem in East and South-East Asia 
and Oceania. Given the dynamic nature of the NPS 
market in the region, as well as most other regions of 
the world, it remains important to share information 
on the emergence of and national responses to NPS. 
This assists Member States to better understand the 
threat of NPS and emerging challenges in the wider 
synthetic drugs market.
22  United Nations Office on Drugs and Crime (UNODC), Annual Re-
port Questionnaire for New Zealand 2013; For a more detailed analy-
sis of  “ecstasy” trends in East and South-East Asia and Oceania, see 
chapter titled “A growing presence of  ecstasy” of  this report.
23  United Nations Office on Drugs and Crime (UNODC), Annual 
Report Questionnaire for Brunei Darussalam, Hong Kong (China), 
Indonesia, the Republic of  Korea, Macau (China), Malaysia, New 
Zealand, Singapore and Thailand 2012 and 2013; Health Sciences 
Authority, “An Overview of  the Drug Situation and Forensic Labora-
tories in Asia”, Singapore, 21 May 2014.
24  United Nations Office on Drugs and Crime (UNODC), Annual 
Report Questionnaire 2011-13; Drug Abuse Information Network 
for Asia and the Pacific (DAINAP); International Narcotics Control 
Board (INCB), Precursor and chemicals frequently used in the illicit manufac-
ture of  narcotic drugs and psychotropic substances 2013, Vienna, March 2014.
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Methamphetamine sold in East and South-East Asia 
is available in two main forms: methamphetamine 
tablets and crystalline methamphetamine. In both 
presentations, methamphetamine is available in 
salt form, most frequently as methamphetamine 
hydrochloride which, in principle, can be smoked, 
nasally insufflated, orally ingested and injected. 
Methamphetamine tablets, commonly known as 
‘yaba’ in the region, are small pills typically of low 
purity weighing about 90 mg which are available 
in many different shapes and colours.25 In addition 
to methamphetamine, such tablets often contain a 
large portion of caffeine and a range of adulterants. 
For methamphetamine tablets, ingestion but also 
smoking of crushed tablets is common. Crystalline 
methamphetamine, also called ‘crystal meth’, ‘ice’ 
or ‘shabu’, is usually of much higher purity than 
the tablet form. On the illicit drug market, it is 
encountered as (crushed) colourless crystals of various 
sizes.26 Information on seizures and use indicate that 
the market for both forms of methamphetamine 
is expanding. Both, methamphetamine tablet and 
crystalline methamphetamine seizures increased in East 
and South-East Asia between 2008 and 2013. Over 
this period crystalline methamphetamine seizures in 
the region almost doubled, while methamphetamine 
tablet seizures have risen at a more rapid rate resulting 
in an eight-fold increase.
2. A diversified market for 
methamphetamine in East and 
South-East Asia
Expert perception indicates high levels of methamphet-
amine tablet and crystalline methamphetamine use in 
East and South-East Asia. In 2013, crystalline metham-
phetamine was the primary drug of concern in Brunei 
Darussalam, Cambodia, Indonesia, Japan, Malaysia, 
the Philippines and the Republic of Korea and the 
second drug of concern in China, Singapore and Viet 
Nam according to expert perception.27 Methamphet-
amine in tablet from was also the primary drug of con-
cern in Cambodia, Lao People’s Democratic Republic 
(PDR) and Thailand and the second drug of concern in 
China and Viet Nam.28
Moreover, in 2013, there was an increase in the use 
of crystalline methamphetamine according to expert 
perception in 7 countries of the region, namely Brunei 
Darussalam, Cambodia, China, the Philippines, the 
Republic of Korea, Singapore and Viet Nam.29 In the 
same year, experts perceived an increased use of meth-
amphetamine tablets in countries of the Greater Me-
kong sub-region, namely Cambodia, China, Lao PDR, 
Figure 3. Crystalline methamphetamine and 
methamphetamine tablet seizures reported in 
East and South-East Asia, 2009-2013
Source(s): Drug Abuse Information Network for Asia and the Pacific 
(DAINAP).
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25  The weight of  90 mg per tablet as a conversion factor which was 
established based on information from forensic laboratories, has 
been used by UNODC since 2011 to convert seizures reported in 
kilograms into tablet equivalent and vice versa in South-East Asia 
(cf. UNODC, World Drug Report 2011, p. 266). A recent analysis of  
methamphetamine samples from over 8,000 seizure cases in Thailand 
in the first half  of  2014 confirmed the continuing validity of  this con-
version factor: almost two-thirds of  the samples had a weight ranging 
between 85.00 and 94.99 mg (official communication with the Office 
of  the Narcotics Control Board, Government of  Thailand, March 
2015).
26  United Nations Office on Drugs and Crime (UNODC), Terminology 
and Information on Drugs. Second edition. New York, 2003; United Na-
tions Office on Drugs and Crime (UNODC), Recommended Methods for 
the Identification and Analysis of  Amphetamine, Methamphetamine and their 
Ring-substituted Analogues in Seized Materials (revised and updated). New 
York, 2006. 
27  Drug Abuse Information Network for Asia and the Pacific (DAINAP).
28  Drug Abuse Information Network for Asia and the Pacific (DAINAP).
29  Drug Abuse Information Network for Asia and the Pacific (DAINAP).
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Myanmar, Thailand and Viet Nam.30 In Myanmar, for 
example, the past-month prevalence of amphetamine-
type stimulant (ATS) use, as reported by survey re-
spondents in poppy-growing regions, tripled between 
2012 and 2014. While this survey is not representa-
tive for the general population, it might indicate an 
increase in the use of methamphetamine tablets.
Differences between methamphetamine tab-
let and crystalline methamphetamine market 
segments
The existence of two forms of presentation of metham-
phetamine in the region, both showing recent increases 
in terms of seizures and use, leads to the question of 
whether they are serving the same or different market 
segments. This chapter discusses differences between 
tablet and crystalline methamphetamine as reflected 
in information on their prices, purity, perceived origin, 
trafficking flows and geographic spread. 
The price and purity of crystalline methamphetamine 
and methamphetamine tablets vary considerably be-
tween countries in the region. A caveat regarding the 
analysis of tablet purity data needs to be made. The ac-
tual weight may vary from tablet to tablet and batch 
to batch as they are produced under clandestine con-
ditions. Considering tablet purity alone can be mis-
leading as tablets of different weights contain different 
amounts of methamphetamine even if the purity is the 
same. However, data on tablet purity is available for 
many countries in the region while the methamphet-
amine amount per tablet is not regularly reported. As 
available information does not indicate large variations 
in tablet weight, tablet purity is used as a proxy indica-
tor for methamphetamine content per tablet.31 On the 
whole, in 2013, similar to previous years, methamphet-
amine tablets were reported to have a purity of 5-20 
per cent, with the remainder often consisting largely 
of caffeine. These tablets are available among the low-
Map 2: Methamphetamine tablet use trends 
according to expert perception, 2013
Source(s): Drug Abuse Information Network for Asia and the Pacific 
(DAINAP).
Map 1: Crystalline methamphetamine use 
trend according to expert perception, 2013
Source(s): Drug Abuse Information Network for Asia and the Pacific 
(DAINAP); Australian Institute of Health and Welfare (AIHW), Illicit use 
of drugs (NDSHS 2013 key findings) and NDSHS 2013 data & references, 
2014 (accessed online at http://www.aihw.gov.au/alcohol-and-other-
drugs/ndshs/2013/illicit-drug-use/); United Nations Office on Drugs 
and Crime (UNODC), Annual Report Questionnaire for Japan 2013; 
Official communication with the National Drug Intelligence Bureau 
(NDIB), New Zealand, October 2014; Official communication with the 
Supreme Prosecutors’ Office (SPO), The Republic of Korea, Narcotics 
Division, October 2014.
Figure 4. Past-month prevalence of ATS use 
among the population aged 15 and above, 
poppy-growing regions, Myanmar, 2012-2014 
Source(s): United Na
ons Office on Drugs and Crime (UNODC), 
Myanmar Central Commiee for Drug Abuse Control, Lao Na
onal 
Commission for Drug Control and Supervision, Southeast Asia 
Opium Survey 2014. Lao PDR, Myanmar, 2014. 
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30  Drug Abuse Information Network for Asia and the Pacific (DAINAP).
Increasing
No trend reported 2012/13
The boundaries and names shown on this map do not imply 
official endorsement or acceptance by the United Nations
Increasing
Stable
Decreasing
No trend reported 2012/13
The boundaries and names shown on this map do not imply 
official endorsement or acceptance by the United Nations
31  See footnote 25.
A DIVERSIFIED MARKET FOR METHAMPHETAMINE IN EAST AND SOUTH-EAST ASIA
7
priced segment of drug markets in East and South-East 
Asia. Nevertheless, prices of methamphetamine tablets 
varied considerably, wherein different levels of purity 
are one example among several contributing factors. 
For instance, in the Mekong sub-region, Viet Nam was 
among the countries to have reported one of the lowest 
retail prices for methamphetamine tablets, ranging be-
tween US$ 1.5 and US$ 3.5 per tablet with an average 
purity of 8-10 per cent.32 Low retail prices for metham-
phetamine tablets were also reported in the northern 
parts of Thailand, close to the border with Myanmar. 
In 2013, methamphetamine tablet samples analyzed by 
forensic laboratories in Thailand had a purity of 10-20 
per cent.33 According to expert perception, metham-
phetamine tablets continued to be the cheapest and 
most widely available illicit drug available in Lao PDR 
and there were indications that prices were decreasing, 
reaching around US$ 2 per tablet in 2013.34 According 
to expert perception, the decline in methamphetamine 
tablet prices in Lao PDR might be due to an increasing 
availability of the drug resulting from large volumes of 
methamphetamine tablets transiting the country from 
Myanmar to other markets.
Some of the highest prices for methamphetamine tab-
lets have been reported by countries outside the Mekong 
sub-region, by countries such as China and Singapore, 
both of which had reported of an average retail price 
above US$ 20 per tablet. However, these comparatively 
high prices might not necessarily be due to a higher pu-
rity. For instance, methamphetamine tablets analyzed in 
Singapore in 2013 had a purity of only 2.4 per cent.35
 
In contrast to methamphetamine tablets, which require 
additional components in the tableting process such as 
binding agents, crystalline methamphetamine can be of 
comparatively high purity. For instance, in 2013, crys-
talline methamphetamine in Thailand reportedly had 
a purity of 40-90 per cent and an average retail price 
of US$ 35-100 per gram.36 In Indonesia, crystalline 
methamphetamine samples tested by forensic laborato-
ries had a purity of 40-53 per cent in 2012.37 In 2013, 
the retail price for one gram of crystalline methamphet-
amine in Indonesia ranged between US$ 200-285.38 
The highest average retail prices per gram of crystalline 
methamphetamine were found in countries outside the 
Mekong sub-region such as in Brunei Darussalam, Ja-
pan and the Republic of Korea while the average re-
tail price in most other South-East Asian countries was 
lower. In Brunei Darussalam, Indonesia, Malaysia, the 
Philippines and Singapore, crystalline methamphet-
amine prices have fluctuated in recent years. The data 
available on methamphetamine prices and purity has 
improved in recent years but does not yet allow for an 
in-depth analysis e.g. calculating purity-adjusted prices. 
Figure 5. Typical retail prices of methamphet-
amine tablets of unknown purity in selected 
countries in East and South-East Asia, 2013 
Note: The high-low bars represent the upper and lower limits of 
the price ranges for those countries which reported such ranges in 
addion to the typical price. 
Source(s): Drug Abuse Informaon Network for Asia and the Pacific 
(DAINAP); China Naonal Narcocs Control Commission (NNCC), 
Ministry of Public Security, “China country presentaon”, present-
ed at the Global SMART Programme regional meeng, Yangon, 
Myanmar, 20-21 August 2014; Central Narcocs Bureau (CNB), 
“Singapore country presentaon”, presented at the Global SMART 
Programme regional meeng, Yangon, Myanmar, 20-21 August 
2014; Standing Office on Drugs and Crime of Vietnam (SODC), 
“Vietnam country presentaon”, presented at the Global SMART 
Programme regional meeng, Yangon, Myanmar, 20-21 August 
2014; Lao Naonal Commission for Drug Control and Supervision 
(LCDC), “Lao PDR country presentaon”, presented at the Global 
SMART Programme regional meeng, Yangon, Myanmar 20-21 
August 2014. 
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32  Standing Office on Drugs and Crime of  Viet Nam (SODC) “Viet Nam 
country presentation”, presented at the Global SMART Programme 
regional meeting, Yangon, Myanmar, 20-21 August 2014.
33  Office of  the Narcotics Control Board of  Thailand (ONCB), “Thai-
land country presentation”, presented at the Global SMART Pro-
gramme regional meeting, Yangon, Myanmar, 20-21 August 2014.
34  Lao National Commission for Drug Control and Supervision (LCDC), 
“Lao PDR country presentation”, presented at the Global SMART 
Programme regional meeting, Yangon, Myanmar 20-21 August 2014.
35  Central Narcotics Bureau (CNB), “Singapore country presentation”, 
presented at the Global SMART Programme regional meeting, Yan-
gon, Myanmar 20-21 August 2014.
36  Office of  the Narcotics Control Board of  Thailand (ONCB), “Thai-
land country presentation”, presented at the Global SMART Pro-
gramme regional meeting, Yangon, Myanmar, 20-21 August 2014.
37  Drug Abuse Information Network for Asia and the Pacific (DAIN-
AP); United Nations Office on Drugs and Crime (UNODC), Annual 
Report Questionnaire for Indonesia in 2013. 
38  National Narcotics Board of  Indonesia (BNN), “Indonesia country 
presentation”, presented at the Global SMART Programme regional 
meeting, Yangon, Myanmar, 20-21 August 2014.
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Tablet and crystalline methamphetamine prices are not 
easily comparable. As with other drugs, users may attri-
bute properties to one or the other form or have usage 
preferences which are not measurable in quantitative 
terms with one-dimensional indicators such as prices. 
Individual consumption patterns, e.g. dosage and fre-
quency of use, can also vary considerably. Still, taking 
these caveats into account and assuming that users may 
take one or a small number of methamphetamine tab-
lets per consumption event, and that a gram of street 
quality crystalline methamphetamine could represent 
about a dozen doses, crystalline methamphetamine in 
Japan, the Republic of Korea and Brunei Darussalam 
seem to be well above tablet prices. However, meth-
amphetamine tablets are not typically encountered in 
these countries. In other countries of the region, par-
ticularly where both forms of methamphetamine are 
commonly available, such as Thailand and Viet Nam, 
the price ranges seem to be much closer. 
Clearly, more investigation is needed to understand if 
and how tablet and crystalline methamphetamine use 
is linked and whether they serve distinct segments of 
the drug market. 
Methamphetamine tablet trafficking – a sub-
regional problem?
Differences between the tablet and crystalline forms of 
methamphetamine also exist in terms of geographical 
area of manufacture and main destination countries 
for trafficking. Methamphetamine tablets are mainly 
manufactured in the Mekong sub-region of East and 
South-East Asia and seizure reports indicate that such 
tablets are mostly intended for markets within this 
sub-region. Myanmar is perceived to be the main 
country of origin for methamphetamine tablets seized 
throughout the Mekong sub-region and to some 
other parts of East and South-East Asia. Reports of 
methamphetamine tablets originating in Myanmar and 
seized in China and Thailand indicate that increasing 
quantities are being trafficked from Myanmar across 
their joint borders.39 By 2013, almost 85 per cent 
of methamphetamine tablets seized in China were 
reported in Yunnan province in China, which signifies 
an 8 per cent increase of seizures reported in this 
province from the previous year.40 Moreover, analysis 
of seized methamphetamine tablets at the National 
Narcotics Laboratory in China in 2013 showed that 
more than 90 per cent of these tablets had originated 
in Myanmar.41 According to government and media 
reports, consignments of methamphetamine tablets are 
frequently discovered inside compartments of motor 
vehicles as well as boats travelling along the Mekong 
Figure 6. Typical retail prices of crystalline 
methamphetamine of unknown purity in 
selected countries in East and South-East 
Asia, 2013 
Note: The high-low bars represent the upper and lower limits of 
the price ranges for those countries which reported such ranges in 
addion to the typical price. Data from the Philippines refers to the 
crystalline methamphetamine price in 2014. Dangerous Drugs 
Board of the Philippines (DDB), “Philippines country presentaon”, 
presented at the Global SMART Programme regional meeng, 
Yangon, Myanmar, 20-21 August 2014.
Source(s): Drug Abuse Informaon Network for Asia and the Pacific 
(DAINAP); Narcocs Control Bureau (NCB), “Brunei Darussalam 
country presentaon”, presented at the Global SMART Programme 
regional meeng, Yangon, Myanmar, 20-21 August 2014; Interna-
onal Safety and Security Cooperaon Division, Ministry of Foreign 
Affairs (MOFA), Japan, August 2014; Supreme Prosecutors’ Office 
(SPO), “Republic of Korea country presentaon”, presented at the 
Global SMART Programme regional meeng, Yangon, Myanmar, 
20-21 August 2014; Central Narcocs Bureau (CNB), “Singapore 
country presentaon”, presented at the Global SMART Programme 
regional meeng, Yangon, Myanmar, 20-21 August 2014; Standing 
Office on Drugs and Crime (SODC), “Viet Nam country presenta-
on”, presented at the Global SMART Programme regional 
meeng, Yangon, Myanmar, 20-21 August 2014.
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39  China National Narcotics Control Commission (NNCC), Ministry 
of  Public Security, Annual Report on Drug Control in China 2014, Bei-
jing, 2014; Official communication with the China National Narcot-
ics Control Commission (NNCC), Ministry of  Public Security, No-
vember 2014; Office of  the Narcotics Control Board of  Thailand 
(ONCB), “Drug situation in Thailand and trends”, presented at the 
Thirty-eighth Meeting of  Heads of  National Drug Law Enforcement 
Agencies, Asia and the Pacific (HONLEA), Bangkok, 21-24 October 
2014.
40  Yunnan province is adjacent to Myanmar, Lao PDR and Viet Nam. 
China National Narcotics Control Commission (NNCC), Ministry of  
Public Security, Annual Report on Drug Control in China 2014, Beijing, 
2014.
41  China National Narcotics Control Commission (NNCC), Ministry 
of  Public Security, Annual Report on Drug Control in China 2014, 
Ministry of  Public Security, Beijing, 2014; Official communication 
with the China National Narcotics Control Commission (NNCC), 
Ministry of  Public Security, November 2014. 
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River. As a response, China, Myanmar, Lao PDR and 
Thailand formed a joint anti-trafficking task force to 
patrol the river in 2011, which has been conducting 
close to 30 joint patrols since then.42 
Given that interdiction efforts have been strengthened 
along the joint border between Myanmar to China and 
Thailand, there are indications that drug traffickers 
have shifted routes to avoid detection. For instance, 
methamphetamine tablets are increasingly being 
trafficked from Myanmar via Lao PDR to China and 
Thailand, and to a lesser extent to Cambodia and Viet 
Nam. In 2014, up to 10 shipments totalling around 
19 million methamphetamine tablets were reported 
to have been seized in Loei Province in Thailand, 
bordering Lao PDR.43 Over the years, Lao PDR has 
become a major transit point for drug trafficking and 
the mountainous parts of the country and riverine 
terrain account for large parts of the country which are 
particularly hard to patrol. In 2013, methamphetamine 
tablet seizures in Lao PDR increased by more than a 
third to over 15 million tablets from about 10 million 
tablets in 2012 and 4.6 million tablets in 2011.44
In Myanmar, methamphetamine tablets are reported 
to be mostly manufactured in the north-eastern Shan 
state, bordering China, Lao PDR and Thailand.45 
Between 2004 and 2013, law enforcement authorities 
in Myanmar have discovered 31 methamphetamine 
tablet pressing machines,46 nearly all of which were 
located in the Shan State. In a recent case reported in 
August 2014, a tableting machine was discovered in the 
Mine Twin village tract of the East Shan State together 
with around 1.6 million methamphetamine tablets, 84 
kg of methamphetamine powder, and large quantities 
of precursor chemicals and other illicit drugs.47 Over the 
years, most dismantled methamphetamine laboratories 
in Myanmar consisted of small-scale mobile facilities 
in areas controlled by active or former ethnic insurgent 
groups.48 Although, annual methamphetamine tablet 
seizures have fluctuated in terms of quantity, the number 
of methamphetamine tablet seizure cases have increased 
between 2007 and 2013, from over 400 cases in 2007 
to over 1,700 cases in 2013.49 Moreover, a recent decline 
was observed in the retail price for methamphetamine 
tablets in Myanmar. In 2013, the average retail price of 
Map 3: Perceived methamphetamine tablet 
trafficking flows to and from countries in 
the Mekong sub-region, 2011-2013*
 
* Not actual trafficking routes.
Source(s): National Authority for Combating Drugs (NACD), “Cambodia 
country report”, presented at the Global SMART Programme regional 
meeting, Yangon, Myanmar, 20-21 August 2014; Lao National Com-
mission for Drug Control and Supervision (LCDC), “Lao PDR country 
presentation”, presented at the Global SMART Programme regional 
meeting, Yangon, Myanmar, 20-21 August 2014; Central Committee 
for Drug Abuse Control (CCDAC), “Myanmar country presentation”, 
presented at the Global SMART Programme regional meeting, Yangon, 
Myanmar, 20-21 August 2014; Standing Office on Drugs and Crime 
(SODC), “Viet Nam country presentation”, presented at the Global 
SMART Programme regional meeting, Yangon, Myanmar, 20-21 August 
2014; Office of the Narcotics Control Board of Thailand (ONCB), “An-
nual Report 2012”, Thailand, December 2013.
42  Xinhua (2011): China launches joint patrols along Mekong River with 
neighbors, 10 Dec 2011.(Accessed online at http://news.xinhuanet.
com/english/china/2011-12/10/c_131298679.htm).
43  Office of  the Narcotics Control Board of  Thailand (ONCB), “Thai-
land country report”, presented at the Thirty-eighth Meeting of  
Heads of  National Drug Law Enforcement Agencies, Asia and the 
Pacific (HONLEA), Bangkok, 21-24 October 2014.
44  United Nations Office on Drugs and Crime (UNODC), Annual Re-
port Questionnaire for Lao PDR 2013. 
45  Central Committee for Drug Abuse Control (CCDAC), “Myanmar 
country presentation”, presented at the Global SMART Programme 
regional meeting, Yangon, Myanmar, 20-21 August 2014.
46  Official communication with Central Committee for Drug Abuse 
Control (CCDAC), April 2015.
47  Central Committee for Drug Abuse Control (CCDAC), “Myanmar 
country presentation”, presented at the Global SMART Programme 
regional meeting, Yangon, Myanmar, 20-21 August 2014.
48  United Nations Office on Drugs and Crime (UNODC,) Transnational 
Organized Crime Threat Assessment in East Asia and the Pacific: A Threat 
Assessment, Bangkok, April 2013.
49  United Nations Office on Drugs and Crime (UNODC), Annual Re-
port Questionnaire for Myanmar 2007 and 2013.
China
Viet Nam
Lao PDR
Cambodia
Thailand
Myanmar
India
Bangladesh
The boundaries and names shown and the designations used on this map 
do not imply official endorsement or acceptance by the United Nations.
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a methamphetamine tablet was about US$ 2, signifying 
a decline from US$ 5 in 2011.50 
Although most methamphetamine seized in Thailand 
is perceived to have originated from Myanmar, 
methamphetamine manufacture has recently also re-
emerged in Thailand. Between 2012 and 2013,11 
methamphetamine laboratories were dismantled,51 
most of which were found in locations close to 
Bangkok, including 5 home-based methamphetamine 
tablet pressing laboratories.52
Methamphetamine tablets were also reportedly 
manufactured in China. According to an analysis 
of seized methamphetamine tablets at the National 
Narcotics Laboratory in China in 2013, around 5 
per cent of these tablets had originated from within 
the country.53 The high availability of ATS precursor 
chemicals in China could increase the risk of their 
diversion for methamphetamine manufacture.54 
In recent years, there have also been reports of 
methamphetamine tablets being possibly manufactured 
in Cambodia and Viet Nam.55 
Emerging developments in the methamphet-
amine tablet market
Recently, there have been some indications of an 
emerging market for methamphetamine tablets in the 
Republic of Korea, Malaysia and Singapore. Although 
the use of methamphetamine tablets in the Republic of 
Korea remains low, methamphetamine tablet seizures 
have recently increased in the country. In 2013, around 
4,000 methamphetamine tablets were seized, which 
marks an almost ten-fold increase from the previous 
year.56 Increasing methamphetamine tablet seizures in 
Malaysia over recent years, also suggest an increasing 
availability for this form of methamphetamine in 
the country. Methamphetamine tablet seizures 
increased significantly since 2011, rising to 525,000 
tablets in 2013.57 According to expert perception, 
methamphetamine tablet use in Malaysia remains 
limited, so that the increase in seizures might be due to 
an increase of transit trafficking.
However, in 2013, most methamphetamine tablet 
seizures in terms of weight were reported by China 
(45%) most of which originated in Myanmar,58 
followed by countries in the Mekong sub-region, such 
as Thailand (44%), Lao PDR (6%) and Myanmar 
(4%).59 Less than 1 per cent of total methamphetamine 
tablet seizures reported in the region were reported in 
Malaysia Cambodia and Viet Nam.
Figure 7. Crystalline methamphetamine 
seizures reported in East and South-East Asia, 
2009-2013
Source(s): Drug Abuse Informaon Network for Asia and the Pacific 
(DAINAP). UNODC Annual Report Quesonnaire for the respecve 
years and countries, 2009-2013. 
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50  Central Committee for Drug Abuse Control (CCDAC), “Myanmar 
country presentation”, presented at the Global SMART Programme 
regional meeting, Yangon, Myanmar, 20-21 August 2014; Official 
communication with the Central Committee for Drug Abuse Control 
(CCDAC), October 2012.
51  Office of  the Narcotics Control Board of  Thailand (ONCB), “Thai-
land country presentation”, presented at the Global SMART Pro-
gramme regional meeting, Yangon, Myanmar, 20-21 August 2014; 
Office of  the Narcotics Control Board of  Thailand (ONCB), Annual 
Report 2012, Thailand, December 2013.
52  Office of  the Narcotics Control Board of  Thailand (ONCB), “Thai-
land country presentation”, presented at the Global SMART Pro-
gramme regional meeting, Yangon, Myanmar, 20-21 August 2014.
53  China National Narcotics Control Commission (NNCC), Ministry 
of  Public Security, “China country report”, presented at the Global 
SMART Programme regional meeting, Yangon, Myanmar, 20-21 Au-
gust 2014.
54  International Narcotics Control Board (INCB), Precursors and chemicals 
frequently used in the illicit manufacture of  narcotic drugs and psychotropic sub-
stances, New York, March 2015.
55  Cambodia and Viet Nam have reported several cases of  metham-
phetamine manufacture and/or attempted manufacture in recent 
years, and tablet pressing machines have been dismantled in both 
countries. However, it is not clear what forms of  ATS were being 
manufactured, due to the paucity of  data in the two countries. 
56  Official communication with the Supreme Prosecutors’ Office (SPO), 
Narcotics Division, October 2014.
57  Official communication with the Royal Malaysia Police (RMP), Octo-
ber 2014. 
58  According to the analysis of  seized methamphetamine tablets by the 
National Narcotics Laboratory in China (China National Narcotics 
Control Commission (NNCC), Ministry of  Public Security, Annual 
Report on Drug Control in China 2014, Ministry of  Public Secu-
rity, Beijing, 2014; Official communication with the China National 
Narcotics Control Commission (NNCC), Ministry of  Public Security, 
November 2014).
59  Drug Abuse Information Network for Asia and the Pacific (DAINAP).
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Complex intra-regional crystalline metham-
phetamine trafficking
Unlike with methamphetamine tablets, which, by and 
large, remained a feature of the Mekong sub-region, 
crystalline methamphetamine has become a geo-
graphically wide-spread drug across East and South-
East Asia. Between 2009 and 2013, the largest share 
of annual crystalline methamphetamine seizures in the 
region were reported by China, annually accounting 
for more than 50 per cent of regional seizures. Crystal-
line methamphetamine seizures in China almost dou-
bled from about 4.5 tons in 2009 to 8 tons in 2013. 
Over the same period, crystalline methamphetamine 
seizures in Thailand have also annually increased from 
0.2 tons in 2009 to 1.7 tons in 2013. Crystalline 
methamphetamine seizures in Japan have more than 
doubled between 2009 and 2013, but seizures have an-
nually remained below 1 ton. In the Philippines, crys-
talline methamphetamine seizures have also increased 
from about 0.1 tons in 2010 to more than 0.8 tons in 
2013. In Indonesia and Malaysia, crystalline metham-
phetamine seizures have annually fluctuated, the larg-
est amount having been reported in Indonesia in 2012 
at more than 2 tons and in Malaysia more recently in 
2013 at 1.7 tons. The question arises whether the ad-
ditional methamphetamine seized was manufactured 
clandestinely within the region or if trafficking from 
other regions also played a role.
Crystalline methamphetamine is reportedly manufac-
tured in some countries in East and South-East Asia. 
In 2013, almost 390 methamphetamine laboratories 
were dismantled in China, a large share of which were 
found to be manufacturing crystalline methamphet-
amine.60 An additional 18 laboratories manufactur-
ing crystalline methamphetamine were dismantled in 
Malaysia.61 Myanmar reported to have dismantled a 
large-scale crystalline methamphetamine laboratory 
in 2012 in the Kokang Special Region of the eastern 
part of the Shan State bordering China62 and there have 
been reports of crystalline methamphetamine seizures 
in other countries of the region that were perceived to 
have originated in Myanmar. According to expert per-
ception, some crystalline methamphetamine manufac-
tured in Myanmar was perceived to have been intended 
for the domestic market. This would represent a new 
development in a market traditionally characterized by 
methamphetamine tablet use.63 Crystalline metham-
phetamine was also perceived to have been trafficked 
from Myanmar to Thailand both for the Thai market as 
well as for onward trafficking.64
From China, crystalline methamphetamine is reported-
ly trafficked to the Philippines and Australia. In 2013, 
more than 0.4 tons of crystalline methamphetamine 
were reported to have been seized in a single seizure 
at Subic Freeport in Zambales in the Philippines.65 
Law enforcement authorities in the Philippines report 
that Chinese drug trafficking networks operating from 
mainland China and Hong Kong (China), are involved 
in the trafficking of crystalline methamphetamine to 
the Philippines.66 In Australia, crystalline methamphet-
amine was the most frequently seized ATS with over 
1.2 tons perceived to have been trafficked from China 
between July 2012 and June 2013.67 Australia identi-
fied Hong Kong (China), and Thailand as the other 
embarkation points for crystalline methamphetamine 
in East and South-East Asia between 2012 and 2013.68
The Republic of Korea is primarily identified as a tran-
sit country for crystalline methamphetamine traffick-
ing. According to the Korea Customs Service (KCS), 
more than half of the crystalline methamphetamine 
seizures reported in 2013 were discovered in the post.69 
All in all, trafficking of crystalline methamphetamine, 
which is manufactured in and destined for the region, 
remains an important feature of the regional market 
and shows an increasingly complex pattern. 
60  China National Narcotics Control Commission (NNCC), Ministry of  
Public Security, “China country presentation”, presented at the Global 
SMART Programme regional meeting, Yangon, Myanmar, 20-21 Au-
gust 2014; National Anti-Drugs Agency of  Malaysia (NADA) and the 
Royal Malaysia Police (RMP), “Malaysia country report”, presented at 
the Global SMART Programme regional meeting, Yangon, Myanmar, 
20-21 August 2014.
61  National Anti-Drugs Agency of  Malaysia (NADA) and the Royal Ma-
laysia Police (RMP), “Malaysia country presentation”,  presented at the 
Global SMART Programme regional meeting, Yangon, Myanmar, 20-
21 August 2014.
62  Official communication with the Myanmar Central Committee for 
Drug Abuse (CCDAC), September 2012. 
63  Official communication with the Myanmar Central Committee for 
Drug Abuse (CCDAC), August 2014. 
64  Official communication with the Office on Narcotics Control Board 
of  Thailand (ONCB), April 2015. 
65  Dangerous Drugs Board (DDB), “Philippine country report”, pre-
sented at the Global SMART Programme regional meeting, Yangon, 
Myanmar, 20-21 August 2014.
66  Dangerous Drugs Board (DDB), “Philippine country report”, pre-
sented at the Global SMART Programme regional meeting, Yangon, 
Myanmar, 20-21 August 2014.
67  Australian Crime Commission (ACC), Illicit Drug Data Report 2012-13, 
Canberra, April 2014.
68  Australian Crime Commission (ACC), Illicit Drug Data Report 2012-13, 
Canberra, April 2014.
69  Korea Customs Service, “Drug Enforcement Activities of  KCS”, 
presented at the Global SMART Programme regional meeting, Yan-
gon, Myanmar, 20-21 August 2014.
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A growing inter-regional dimension of crys-
talline methamphetamine trafficking
Although crystalline methamphetamine continues to be 
manufactured within the region on a large scale, a com-
plex international trafficking pattern of crystalline meth-
amphetamine, originating in other parts of the world, 
has evolved in recent years. Large amounts of crystalline 
methamphetamine were perceived to have been trafficked 
to East and South-East Asia from Western Africa, West-
ern Asia, North America, and, more recently, South Asia. 
For some years, crystalline methamphetamine has been 
trafficked from Africa to a number of countries in East and 
South-East Asia, such as Cambodia, China, Japan, Malaysia, 
Thailand, Viet Nam, and, more recently, the Philippines.70 In 
Map 4: Inter-regional crystalline methamphetamine flows as perceived by recipient 
countries to East and South-East Asia and Oceania, 2011-2013* 
* Not actual trafficking routes. Perceived region of origin may not be region of manufacture.
Source(s): United Nations Office on Drugs and Crime (UNODC), 2014 Global Synthetic Drugs Assessment: Amphetamine-type stimulants and 
new psychoactive substances, Vienna, May 2014; , Standing Office on Drugs and Crime (SODC), “Viet Nam country report”, presented at the 
Global SMART Programme regional meeting, Yangon, Myanmar, 20-21 August 2014; The Office of the Narcotics Control Board of Thailand (ONCB), 
”Thailand country report”, presented at the Global SMART Programme regional meeting, Yangon, Myanmar, 20-21 August 2014;;; Australian Crime 
Commission (ACC), “Illicit Drug Data Report 2012-13”, Canberra, April 2014; National Narcotics Board of Indonesia (BNN), “Indonesia country 
presentation”, presented at the Global SMART Programme regional meeting, Yangon, Myanmar, 20-21 August 2014; International Safety and 
Security Cooperation Division, Ministry of Foreign Affairs (MOFA), Japan, August 2014; National Anti-Drugs Agency of Malaysia (NADA) and the 
Royal Malaysia Police (RMP), “Malaysia country presentation”, presented at the Global SMART Programme regional meeting, Yangon, Myanmar, 
20-21 August 2014; Supreme Prosecutors’ Office (SPO), “Republic of Korea country report”, presented at the Global SMART Programme regional 
meeting, Yangon, Myanmar, 20-21 August 2014; Dangerous Drugs Board of the Philippines (DDB), “Philippines country report”, presented at the 
Global SMART Programme regional meeting, Yangon, Myanmar, 20-21 August 2014. 
Australia
Indonesia
Malaysia
Thailand
Japan
Viet NamMiddle 
East
Europe
Western
Africa
Southern
Africa
Republic 
of Korea
Western
Asia North
America
South
Asia
Philippines
Eastern
Africa
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70  National Authority for Combating Drugs (NACD), “Cambodia country 
presentation”, presented at the Global SMART Programme Regional 
Workshop, Jakarta, 28-29 August 2013; China National Narcotics Con-
trol Commission (NNCC), Ministry of  Public Security, “China country 
report”, presented at the Global SMART Programme regional meeting, 
Yangon, Myanmar, 20-21 August 2014; Standing Office on Drugs and 
Crime of  Vietnam (SODC), “Vietnam country presentation”, presented 
at the Global SMART Programme regional meeting, Yangon, Myan-
mar, 20-21 August 2014; Dangerous Drugs Board (DDB), Office of  the 
President and the Philippine Drug Enforcement Agency (PDEA), “The 
Philippine Drug Situation”, presented at the Global SMART Programme 
Regional Workshop, Phnom Penh, 24-25 July 2012; Op. cit. PDEA coun-
try report, February 2014; United Nations Office on Drugs and Crime 
(UNODC), 2014 Global Synthetic Drugs Assessment: Amphetamine-type stimu-
lants and new psychoactive substances, Vienna, May 2014.
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Malaysia, in Kuala Lumpur, law enforcement authorities 
reported to have seized around 70 kg of crystalline 
methamphetamine in April 2014 which was perceived 
to have originated from Lagos, in Nigeria.71 According 
to expert perception, there has been an increase of 
crystalline methamphetamine seizures in Thailand in 
2013 perceived to have originated in African countries.72 
Crystalline methamphetamine trafficking by African 
drug trafficking networks has also been reported by 
Cambodia, the Republic of Korea and Viet Nam in 
2013.73
In recent years, East and South-East Asian countries 
have also reported of crystalline methamphetamine 
seizures perceived to have originated from Western 
Asia. Recently, there have been reports of large 
crystalline methamphetamine seizures perceived to 
have originated from the Islamic Republic of Iran 
that have been trafficked by ship. Indonesian law 
enforcement authorities, for example, have reported 
seizures of methamphetamine shipments perceived 
to have originated from the Islamic Republic of Iran, 
including 40 kg in February 2014.74 
For some years, large shipments of crystalline 
methamphetamine, perceived to have originated 
in Mexico were reported to have been seized in 
some parts of East and South-East Asia.75 In 2013, 
consignments totaling more than 0.4 tons of crystalline 
methamphetamine perceived to have originated from 
Mexico were reported to have been seized in Japan,76 
followed by another crystalline methamphetamine 
seizure reported in Japan in March 2014, consisting 
of almost 0.2 tons of crystalline methamphetamine 
perceived to have originated from Mexico.77 Law 
enforcement authorities in the Philippines have 
reported of a methamphetamine laboratory that 
was dismantled in the country in 2012 operated by 
a Chinese drug trafficking group that was found to 
have connections with a Mexican criminal network.78 
The Republic of Korea has also seized around 15 kg 
of crystalline methamphetamine in 2013, perceived to 
have originated from Mexico.79 According to a report 
by the Australian Crime Commission, Mexican drug 
cartels involved in methamphetamine trafficking 
have actively sought criminal partners in Australia to 
import the drug into the country.80 In addition, some 
countries in East and South-East Asia, such as Japan81, 
have reported seizures of crystalline methamphetamine 
that were perceived to have originated from India.
On the whole, it seems reasonable to assume that 
lower priced methamphetamine tablets in East and 
South East Asia might be more attractive in lower 
income countries or to lower income groups of the 
population while crystalline methamphetamine 
appears to be more typical for higher income countries 
where its higher price and purity might be more 
affordable. While both the methamphetamine tablet 
and crystalline methamphetamine market segments 
seem to be expanding, the inter-regional dimension of 
trafficking has so far remained a feature of crystalline 
methamphetamine.
A number of questions arise from this development. Is 
more methamphetamine originating in Mexico shipped 
towards Asia because stagnating or even declining 
consumption of crystalline methamphetamine in 
North America is not absorbing the large amounts 
manufactured? Is the growing economic prosperity 
in many Asian countries and their large, young 
population attracting drug traffickers more than other 
regions? Clearly, the current dynamics of the crystalline 
methamphetamine market in East and South-East 
Asia and Oceania can no longer be explained with 
71  Official communication with the National Anti-Drugs Agency 
(NADA),  August  2014.
72  United States Department of  State, Bureau of  International Narcot-
ics and Law Enforcement Affairs, International Narcotics Control 
Strategy Report, March 2014.
73  National Authority for Combating Drugs (NACD), “Cambodia 
country presentation”, presented at the Global SMART Programme 
Regional Workshop, Jakarta, 28-29 August 2013; International Safe-
ty and Security Cooperation Division, Ministry of  Foreign Affairs 
(MOFA),  Japan,  August 2014; Supreme Prosecutors’ Office (SPO), 
“Republic of  Korea country presentation”, presented at the Global 
SMART Programme regional meeting, Yangon, Myanmar, 20-21 Au-
gust 2014; Standing Office on Drugs and Crime of  Vietnam (SODC), 
“Vietnam country presentation”, presented at the Global SMART 
Programme regional meeting, Yangon, Myanmar, 20-21 August 2014.
74  National Narcotics Board of  Indonesia (BNN), “Indonesia country 
report”, presented at the Global SMART Programme regional meet-
ing, Yangon, Myanmar, 20-21 August 2014; United Nations Office on 
Drugs and Crime (UNODC), 2014 Global Synthetic Drugs Assessment: 
Amphetamine-type stimulants and new psychoactive substances, Vienna, May 
2014.
75  Supreme Prosecutors’ Office (SPO), “Republic of  Korea country 
presentation”, presented at the Global SMART Programme regional 
meeting, Yangon, Myanmar, 20-21 August 2014.
76  International Safety and Security Cooperation Division, Ministry of  
Foreign Affairs (MOFA), Japan, August 2014.
77  National Police Agency of  Japan (NPA), October 2014. 
78  Dangerous Drugs Board (DDB), “Philippine country report”, pre-
sented at the Global SMART Programme Regional Workshop, Ja-
karta, 28-29 August 2013.
79  Supreme Prosecutors’ Office (SPO), “Republic of  Korea country 
presentation”, presented at the Global SMART Programme regional 
meeting, Yangon, Myanmar, 20-21 August 2014.
80  Australian Crime Commission, “The Australian Methylamphetamine Mar-
ket. A National Picture”, 2015. 
81  International Safety and Security Cooperation Division, Ministry of  
Foreign Affairs (MOFA), Japan, August 2014.
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an intra-regional approach and global developments 
on the drug market need to be included into the 
analysis. More research and information is needed to 
better understand the differences in market features 
and the use patterns of crystalline methamphetamine 
and methamphetamine tablets, as these may require a 
diverse set of responses from law enforcement, as well 
as health and treatment providers.
The footprint of methamphetamine use in 
treatment data
Methamphetamine use in both crystalline and tablet 
form continues to be a major problem in large parts 
of East and South-East Asia. Methamphetamine users 
account for a large share of people receiving drug 
treatment in a number of countries. In 2013, China, 
Myanmar and the Philippines reported an increase 
of people receiving treatment for methamphetamine 
use from the previous year.82 For instance, in China 
the number of registered methamphetamine users 
increased by more than 40 per cent in 2013 since 
2012.83 Moreover, people receiving treatment for 
methamphetamine use accounted for the largest share 
of people treated for drug use in 2013 in Lao PDR at 98 
per cent, the Republic of Korea at 96 per cent, Brunei 
Darussalam at 96 per cent, Cambodia at 94 per cent, 
Indonesia at 80 per cent, Thailand at 90 per cent,84 and 
the Philippines at 83 per cent.85 According to expert 
perception, methamphetamine is the most commonly 
used drug among young drug users and among drug 
users arrested for the first time in Singapore in 2013.86
The presence of methamphetamine tablets in the 
Mekong sub-region is reflected in data available on 
treatment. For instance, around 84 per cent of people 
receiving drug treatment in Thailand in 2013 had 
used methamphetamine tablets.87 Methamphetamine 
tablets are also of major concern in Lao PDR with 
users annually accounting for 95 per cent of people 
treated for drug use in recent years.88 Moreover, in 
2013, methamphetamine tablet users accounted for 
more than 98 per cent of people treated for drug use at 
the Somsanga Treatment and Rehabilitation Center, in 
Vientiane, in Lao PDR.89 
With regards to crystalline methamphetamine, 
treatment data shows that this drug is becoming of 
growing concern for countries across East and South-
East Asia and Oceania. For instance, in the Philippines, 
crystalline methamphetamine users accounted for 
around 75 per cent of people receiving drug treatment 
in 2013, which marks an increase of about 25 per 
cent from the previous year.90 Although the share of 
people treated for crystalline methamphetamine use 
in Indonesia is far lower at around 25 per cent, this 
still signifies an increase of almost 80 per cent from 
the previous year. Crystalline methamphetamine users 
also accounted for the second largest share of newly 
admitted patients receiving drug treatment in 2013 
at 31 per cent, after heroin users who accounted for 
a 36 per cent share.91 Moreover, in China, crystalline 
methamphetamine users accounted for 70 per cent of 
synthetic drug users receiving treatment in 2013, while 
methamphetamine tablet users accounted for about 16 
per cent.92 Among recent drug users aged 14 or older in 
Australia in 2013, crystalline methamphetamine had 
an annual use of 50 per cent, which marks a significant 
increase from the 22 per cent annual use of crystalline 
methamphetamine among this group of recent drug 
users in 2010.93
In 2011, the Central Committee for Drug Abuse 
Control (CCDAC) in Myanmar conducted a 
study of methamphetamine users who had recently 
received treatment for drug use which found that 
69 per cent were poly-drug users.94 With regards to 
methamphetamine tablets, smoking95 was found 
to be the most common mode of administration 
among this group of methamphetamine users in 
this study at almost 97 per cent, while injecting use 
82  Drug Abuse Information Network for Asia and the Pacific (DAINAP).
83  China National Narcotics Control Commission (NNCC), Ministry of  
Public Security, Annual Report on Drug Control in China 2014, Bei-
jing, 2014.
84  Drug Abuse Information Network for Asia and the Pacific (DAINAP).
85  United Nations Office on Drugs and Crime (UNODC), Annual Re-
port Questionnaire (ARQ) for the Philippines in 2014.
86  Central Narcotics Bureau Press Release, Singapore Central Narcotics 
Bureau (CNB), Singapore, February 2014 (updated May 2014) (Ac-
cessed at: http://www.cnb.gov.sg/Libraries/CNB_Newsroom_Files/
CNB_2013_Stats_Release_final_updated_as_of_15_May_2014.sflb.
ashx).
87  Drug Abuse Information Network for Asia and the Pacific (DAINAP).
88  Drug Abuse Information Network for Asia and the Pacific (DAINAP).
89  Lao National Commission for Drug Control and Supervision (LCDC), 
“Lao PDR country presentation”, presented at the Global SMART 
Programme regional meeting, Yangon, Myanmar 20-21 August 2014. 
90  United Nations Office on Drugs and Crime (UNODC), Annual Re-
port Questionnaire (ARQ) for the Philippines in 2014; Drug Abuse 
Information Network for Asia and the Pacific (DAINAP).
91  Drug Abuse Information Network for Asia and the Pacific (DAINAP).
92  Drug Abuse Information Network for Asia and the Pacific (DAINAP).
93  Australian Institute of  Health and Welfare (AIHW), Illicit use of  drugs 
(NDSHS 2013 key findings) and NDSHS 2013 data & references, 2014 
(accessed online at http://www.aihw.gov.au/alcohol-and-other-drugs/
ndshs/2013/illicit-drug-use.
94  The study was conducted jointly by the CCDAC, Myanmar Ministry of  
Health, the UNODC Global SMART Programme and local NGOs.
95  The tablets are typically crushed and then vaporized in glass pipes or on 
aluminum foil heated by a flame underneath so that the user can inhale 
the resulting fumes.
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accounted for the mode of use for less than 1 per cent 
of methamphetamine users.96 According to expert 
perception, smoking has also been the most common 
mode of methamphetamine tablet use in Thailand 
for several years, followed by oral ingestion. Injecting 
crystalline methamphetamine and methamphetamine 
tablets remained a limited mode of use in Thailand in 
2013.97 Data remains limited with regards to recent 
developments of poly drug use and injecting drug use 
involving methamphetamine. These particular forms 
of drug use pose a serious challenge for treatment and 
health providers and more information and data is 
needed to design effective responses.
Treatment figures are difficult to interpret, an 
important caveat being that the overall prevalence of 
methamphetamine use and the proportion of users 
consuming methamphetamine in tablet form as 
opposed to crystalline methamphetamine among the 
general population is not known. Still, the available 
data indicate the importance of both forms of 
methamphetamine for treatment demand in the region, 
which, based on the analysis of the methamphetamine 
market presented is likely to increase. 
96  The study was conducted jointly by the CCDAC, Myanmar Ministry of  
Health, the UNODC Global SMART Programme and local NGOs.
97  Drug Abuse Information Network for Asia and the Pacific (DAINAP).
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Seizure and use data indicate that the “ecstasy” market 
in East and South-East Asia has gained in importance. 
Europe and the Americas (primarily North America) 
together used to make up the largest amount of “ec-
stasy” seized worldwide, annually accounting for more 
than 80 per cent of global “ecstasy” seizures between 
2009 and 2011, while East and South-East Asia and 
Oceania as a whole accounted for most of the remain-
der. And yet, in 2012, “ecstasy” seizures in the region 
have surged to almost 2 tons, just below the amount 
seized in Europe at 2.3 tons, but far higher than that 
seized in the Americas at 0.9 tons. In 2013, “ecstasy” 
seizures in East and South-East Asia and Oceania 
amounted to almost 1 ton, which was less than the 
year before but still at a higher level than between 
2009 and 2011 when “ecstasy” seizures in the region 
annually remained below 0.8 tons. In 2014, law en-
forcement authorities in Australia and Myanmar have 
also reported of multi-ton “ecstasy” seizures.98 East 
and South-East Asia and Oceania might be becoming 
an emerging driver of the global market for “ecstasy”, 
though “ecstasy” seizures continue to only comprise a 
fraction of ATS seizures in the region.
However, seizures alone do not provide a direct 
indication for the size of a drug market. Therefore, 
an increase of “ecstasy” seizures in certain countries of 
East and South-East Asia might not necessarily be due 
to a growing domestic demand, but could instead be 
the result of growing domestic “ecstasy” manufacture, 
an expansion of transit trafficking or improved efforts 
in law enforcement. This chapter will start by assessing 
the demand for “ecstasy” in the region, followed by 
an analysis of the possible effects of NPS on “ecstasy” 
markets as well as investigating trends in the supply for 
“ecstasy” to the region.
3. A growing presence of “ecstasy”
Is the “ecstasy” market expanding?
These last few years, significant, and yet, steady levels 
of “ecstasy” use have been reported in Australia and 
New Zealand. The most recent 2013 Australian 
National Drug Strategy Household Survey found that 
“ecstasy”, as in the previous survey in 2010, continues 
to be the second most used drug among people aged 
14 and over, at an annual prevalence of 2 per cent, after 
cannabis at 16 per cent.99 In New Zealand, the latest 
drug use survey conducted in the country between 
2007/08 showed that in terms of annual prevalence 
“ecstasy” was also the third most used substance among 
people aged 16 to 64 at 2.6 per cent, after cannabis at 
14.6 per cent and hallucinogens at 3.2 per cent.100
In spite of relatively high levels of “ecstasy” use in 
Australia and New Zealand, recent “ecstasy” seizures 
in both countries have not been the main contributors 
of the higher level of “ecstasy” seizures in the region 
in 2012 and 2013. A country-by-country breakdown 
Figure 8. “Ecstasy” seizures reported worldwide, 
by region, 2009-2013
Source(s): United Na
ons Office on Drugs and Crime (UNODC), 
Annual Report Ques
onnaire 2009-2013.
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98  Australian Federal Police, “Media Release: Drugs worth $1.5 billion 
seized by Joint Organised Crime Group”, 29 November 2014; Of-
ficial Government communication with the Myanmar Central Com-
mittee for Drug Abuse Control (CCDAC), March 2015.
99  Australian Institute of  Health and Welfare (AIHW), “Alcohol and other 
drug treatment services in Australia 2012-13”, Canberra, 2014.
100  Ministry of  Health of  New Zealand, “Drug Use in New Zealand: Key 
results of  the 2007/08 New Zealand Alcohol and Drug Use Survey”, Wel-
lington, January 2010.
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of “ecstasy” seizures in East and South-East Asia and 
Oceania shows that the higher levels are primarily 
attributable to a surge of seizures in Indonesia, having 
more than doubled to 0.3 tons in 2011 and reaching 
1.3 tons in 2012, the largest amount of “ecstasy” seized 
in the world that year. “Ecstasy” seizures in Australia 
have remained steady at around 0.1 tons between 
2010 and 2012, rising to 0.3 tons in 2013. In contrast, 
seizures in China have decreased from 0.3 tons in 2009 
to 0.1 tons in 2013. Together, all other countries in the 
region have annually accounted for less than 0.1 tons 
of “ecstasy” seizures.
“Ecstasy” seized by a number of countries in the region 
in 2012 was reportedly entirely intended for supplying 
domestic markets. All “ecstasy” seized in Hong Kong 
(China), Indonesia, Japan, New Zealand and Singapore 
that year, was destined for the domestic market.101 This 
continued to be a trend for Hong Kong (China), New 
Zealand and Singapore in 2013, where all “ecstasy” 
seized in these countries was reported to have been 
intended for the domestic market.102 “Ecstasy” seizures 
in most of these countries consisted of amounts less 
than 5 kg in both years.103
There remains insufficient data available to establish 
the size of the “ecstasy” market in the region based 
on use figures. In Indonesia, use data of specific 
population groups suggests widespread use. The 
National Survey on Drug Abuse and Illicit Trafficking 
among Workers of Transportation Modes (Land, Sea 
and Air) in 2013, found that “ecstasy” was the second 
most used drug in terms of annual prevalence at 1.4 
per cent, after cannabis at 4.9 per cent.104 Moreover, 
in this survey “ecstasy” was identified as the drug 
of first use by 1.3 per cent of the respondents, after 
cannabis at 11.9 per cent.105 In 2012, the results of a 
drug use survey among Indonesian workers aged 15 to 
60 ranked “ecstasy” as the second most used drug in 
terms of annual prevalence at 1.02 per cent together 
with methamphetamine, after cannabis at 3.50 per 
cent.106 Among students aged 15 to 19, a school survey 
in Indonesia in 2011 identified the annual prevalence 
of “ecstasy” as the second most used drug together 
with benzodiazepines at 0.34 per cent, after cannabis 
at 1.30 per cent. In this survey, “ecstasy” use at 0.34 per 
cent ranked higher than that for methamphetamine at 
0.26 per cent.107 
Though there has been a reported increase of “ecstasy” 
seizures in Malaysia in 2012, “ecstasy” was identified 
as the least used ATS in 2010 and 2012 according 
to expert perception.108 However, Malaysia has been 
identified as a transit country for “ecstasy” seized 
by several countries in the region in recent years. In 
Singapore, almost all of the “ecstasy” seized in 2012 
and 2013, and almost two-thirds of the “ecstasy” seized 
in 2011 had been reportedly trafficked via Malaysia.109 
Furthermore, all “ecstasy” seized in Brunei Darussalam 
in 2011 and 2013, and a quarter of “ecstasy” seized 
in New Zealand in 2011 had reportedly also been 
trafficked via Malaysia.110 Therefore, the increase of 
seizures in Malaysia might point to growing transit 
trafficking of “ecstasy”.
Figure 9. “Ecstasy” seizures reported in East 
and South-East Asia and Oceania, 2009-2013
Source(s): United Na
ons Office on Drugs and Crime (UNODC), 
Annual Report Ques
onnaire 2009-2013.
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101  United Nations Office on Drugs and Crime (UNODC), Annual Re-
port Questionnaire for Hong Kong (China), Indonesia, Japan, New 
Zealand and Singapore 2012.
102  United Nations Office on Drugs and Crime (UNODC), Annual Re-
port Questionnaire for Hong Kong (China), New Zealand and Singa-
pore 2013.
103  In 2012, Hong Kong (China) had reported 0.4 kg of  “ecstasy” 
seizures, Japan 1.1 kg and Singapore 1.2 kg. In 2013, Hong Kong 
(China) had reported 1.6 kg of  “ecstasy” seizures and Singapore 2.3 
kg; United Nations Office on Drugs and Crime (UNODC), Annual 
Report Questionnaire Hong Kong (China), Japan and Singapore 2012 
and 2013.
104  National Narcotics Board, “Journal of  Data on the Prevention and Eradi-
cation of  Drug Abuse and Illicit Trafficking: Year 2013”, Indonesia, June 
2014.
105  National Narcotics Board, “Journal of  Data on the Prevention and Eradi-
cation of  Drug Abuse and Illicit Trafficking: Year 2013”, Indonesia, June 
2014.
106  United Nations Office on Drugs and Crime (UNODC), Annual Re-
port Questionnaire for Indonesia 2012.
107  United Nations Office on Drugs and Crime (UNODC), Annual Re-
port Questionnaire for Indonesia 2012.
108  United Nations Office on Drugs and Crime (UNODC), Annual Re-
port Questionnaire for Malaysia 2010 and 2012.
109  United Nations Office on Drugs and Crime (UNODC), Annual Re-
port Questionnaire for Singapore 2011-13.
110  United Nations Office on Drugs and Crime (UNODC), Annual Re-
port Questionnaire for Brunei Darussalam and New Zealand 2011-
13.
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Recently, there are indications of “ecstasy” use in the 
Mekong sub-region. According to expert perception 
in 2012, “ecstasy” use had increased in Cambodia, 
Thailand and Viet Nam111 but this was not confirmed 
for 2013112 and “ecstasy” seizures in Cambodia 
and Thailand and Viet Nam have remained at a 
comparatively between 2009 and 2013.
Are there different types of “ecstasy” in the 
market?
Some NPS contain molecules that might share sim-
ilar effects and profiles of MDMA that they are de-
signed to mimic. For instance, synthetic cathinones 
can evoke stimulant and empathogenic effects similar 
to ATS, including MDMA.113 In East and South-East 
Asia and Oceania, there are increasing reports of seized 
“ecstasy” tablets that have been found to contain little 
or no MDMA and consist mainly of a blend of non-
controlled substances. In 2012, only Hong Kong (Chi-
na), Indonesia, New Zealand and Singapore reported 
the presence of NPS adulterants in “ecstasy” tablets. 
In 2013, such reports were also received from Brunei 
Darussalam, the Republic of Korea, Macau (China), 
Malaysia and Thailand.114 In both 2012 and 2013, al-
most all countries had identified piperazines (such as 
BZP115 and TFMPP116) in seized “ecstasy” tablets. Syn-
thetic cannabinoids (such as JWH-018117) and syn-
thetic cathinones (such as mephedrone (4-MMC) and 
methylone118) were other NPS groups that had been 
frequently found in seized “ecstasy” tablets.119 Overall, 
it remains unclear whether certain NPS are replacing 
MDMA, in either the short or long term, or whether 
they are simply being used to supplement the “ecstasy” 
market. 
A closer look at the “ecstasy” market in New Zealand, 
points to a diversified market in which two types of 
“ecstasy” might be present. According to the National 
Drug Intelligence Bureau in New Zealand, “ecstasy” 
is increasingly being trafficked in the form of orders 
over the internet by individuals and small networks 
who in this way do not rely on domestic manufacture 
of the drug.120 The authorities in New Zealand believe 
that this may reflect a market niche for higher quality 
“ecstasy” tablets in the country with actual MDMA 
content, especially considering that roughly half of the 
“ecstasy” seized was perceived to have been trafficked 
from the Netherlands (where ecstasy mostly contains 
MDMA).121
Whilst “ecstasy” trafficked to New Zealand from 
other regions of the world are found to have a high 
MDMA content, the drop in “ecstasy” prices in New 
Zealand might reflect “ecstasy” of low MDMA purity 
manufactured in the country. This assumption would 
be supported by the fact that between 2008 and 
2012, “ecstasy” seizures in New Zealand have been 
Figure 10. “Ecstasy” seizures and typical street 
price per “ecstasy” tablet in New Zealand, 
2008-2012
Source(s): United Na
ons Office on Drugs and Crime (UNODC), 
Annual Report Ques
onnaire 2008-12; Typical street price per 
“ecstasy” tablet was not reported for 2009 and 2013.
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111  United Nations Office on Drugs and Crime (UNODC), Annual Re-
port Questionnaire for Cambodia, Thailand and Viet Nam 2012.
112  Drug Abuse Information Network for Asia and the Pacific (DAINAP). 
113  For more information on the stimulant and empathogenic effects of  
mephedrone see Brunt, Tibor M. et. al. “Instability of  the ecstasy mar-
ket and a new kid on the block: mephedrone”,  Journal of  Psychopharma-
cology 25 (Sep 2010): 1543-1547; Schifano, Fabrizio, et.al. “Mephedrone 
(4-methylmethcathinone; ‘meow meow’): chemical, pharmacological 
and clinical issues”, Journal of  Psychopharmacology 214 (April 2011): 593-
602.
114  United Nations Office on Drugs and Crime (UNODC), Annual Re-
port Questionnaire 2012 and 2013; Health Sciences Authority, “An 
Overview of  the Drug Situation and Forensic Laboratories in Asia”, 
Singapore, 21 May 2014.
115  1-Benzylpiperazine (BZP) is a piperazine not under international con-
trol at the time of  drafting this report. 
116  1-(3-Trifluoromethylphenyl)piperazine (TFMPP) is a piperazine not 
under international control.
117  JWH-018 is the chemical abbreviation of  (1-Pentyl-1H-indol-3-yl)-
1-naphthalenyl-methanone), a synthetic cannabinoid not under inter-
national control at the time of  drafting this report.
118   3,4-Methylenedioxy-N-methcathinone (bk-MDMA), also known as 
methylone is a synthetic cathinone not under international control at 
the time of  drafting this report.
119  United Nations Office on Drugs and Crime (UNODC), Annual Re-
port Questionnaire 2012 and 2013; Health Sciences Authority, “An 
Overview of  the Drug Situation and Forensic Laboratories in Asia”, 
Singapore, 21 May 2014.
120  United Nations Office on Drugs and Crime (UNODC), Annual Re-
port Questionnaire for New Zealand 2013.
121  United Nations Office on Drugs and Crime (UNODC), Annual Re-
port Questionnaire for New Zealand 2013; Reported to the EMCD-
DA by the Reitox National Focal Point of  the Netherlands, Euro-
pean Monitoring Centre for Drugs and Drug Addiction (EMCDDA), 
2012.
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steadily increasing from about 4 kg to just under 50 
kg. However, the typical street price per tablet has 
dropped from about US$ 43 to US$ 16 over the same 
period.122 The increase in seizures accompanied by 
falling prices usually implies an increased availability of 
“ecstasy”. However, it could be that lower prices since 
2010 were reflecting “ecstasy” tablets of low MDMA 
purity manufactured in the country and not changes 
in availability. For instance, a laboratory believed to be 
intended for the supply of “ecstasy” tablets discovered 
in New Zealand in November 2012, was in fact 
manufacturing NPS that were sold as “ecstasy”.123 
“Ecstasy” seizures in New Zealand have dropped to 
around 5 kg in 2013, but given that the typical street 
price per “ecstasy” tablet was not reported that year, the 
trend for 2013 remains unknown.124
It might be that New Zealand has a two-pronged market 
in which “ecstasy” high in MDMA is being supplied 
from countries outside the region, predominantly 
Western Europe, and “ecstasy” containing various 
controlled and non-controlled substances is being 
manufactured domestically. So far, there is not enough 
information available to establish whether the growing 
availability of NPS in New Zealand and other countries 
in the region may have impacted the “ecstasy” market. 
What is the extent of “ecstasy” manufacture in 
the region?
Over the last few years, “ecstasy” manufacture has been 
reported by a number of countries in the region. In 
Australia, 16 MDMA laboratories were dismantled in 
2011, but only another 2 the following year.125 In total, 
6 “ecstasy” laboratories were dismantled in Malaysia 
in 2011 and 2012 respectively and another 8 “ecstasy” 
or undefined ATS laboratories were dismantled in 
2013.126 In Indonesia, 5 “ecstasy” laboratories were 
dismantled in 2011 declining to 2 in 2012 (some of 
which were reported to be of “kitchen”-size), while one 
laboratory was dismantled in New Zealand in 2012 
and another 2 in 2013.127 Overall, there has been a 
decrease in the number of discovered illicit laboratories 
in the region from 27 in 2011 to 12 the following 
year, mostly due to the drop reported in Australia and 
Indonesia. Given that the size of most laboratories is 
unknown, the sheer number of dismantled “ecstasy” 
laboratories does not indicate the quantity produced 
in the region. Therefore, it is difficult to establish the 
extent of “ecstasy” manufacture in the region based on 
the number of dismantled laboratories.
However, in the last few years there have been significant 
seizures of ecstasy precursor chemicals in the region. The 
primary precursor chemicals used in the manufacture 
of MDMA and its analogues, MDA and MDEA, are 
safrole (including in the form of safrole rich oils), iso-
safrole, piperonal and 3,4-MDP-2-P128. Between 2008 
and 2010, ecstasy precursor chemical seizures annually 
remained below 90 litres, but in 2011 seizures surged 
to over 58,000 litres and still reached 8,000 litres in 
2012.129 This significant increase in ecstasy chemical 
Figure 11. Safrole and 3,4-MDP-2-P seizures 
(litres) reported in East and South-East Asia 
and Oceania, by country, 2011-2012
Source(s): Internaonal Narcocs Control Board (INCB), Precursor 
and chemicals frequently used in the illicit manufacture of narcoc 
drugs and psychotropic substances 2013, Vienna, March 2014.
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122  The typical street price per “ecstasy” tablet was not reported for 2013. 
Whether there have been any changes in the purity of  “ecstasy” tablets 
in New Zealand is unknown.
123  United Nations Office on Drugs and Crime (UNODC), Annual Re-
port Questionnaire for New Zealand 2012.
124  There was insufficient information to understand the potential impact 
of  the introduction of  the Psychoactive Substance Act 2013 in New 
Zealand on the ecstasy market. The available information suggests that 
many products containing NPS which received interim licenses after 
the introduction of  the Act (all of  which were revoked by May 2014) 
actually contained synthetic cannabinoids rather than NPS with similar-
ities to ecstasy-type of  substances. See Wilkins, C. (2014). “The interim 
regulated legal market for NPS (‘legal high’) products in New Zealand: 
The impact of  new retail restrictions and product licensing.” Drug Test 
Anal 6(7-8): 868-875 and http://psychoactives.health.govt.nz.
125  United Nations Office on Drugs and Crime (UNODC), Annual Re-
port Questionnaire for Australia 2012.
126  United Nations Office on Drugs and Crime (UNODC), Annual Re-
port Questionnaire 2011-13; Drug Abuse Information Network for 
Asia and the Pacific (DAINAP).
127  United Nations Office on Drugs and Crime (UNODC), Annual Re-
port Questionnaire 2011-13.
128  3,4-MDP-2-P is the chemical abbreviation of  3,4-methylenedioxyphe-
nyl-2-propanone.
129  International Narcotics Control Board (INCB), Precursor and chemicals 
frequently used in the illicit manufacture of  narcotic drugs and psychotropic sub-
stances 2013, Vienna, March 2014.
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Chemical precursor diversion from licit trade
The majority of chemical precursors for ecstasy seized in East and South-East Asia and Oceania between 
2007 and 2012 consisted of safrole, while 3,4-MDP-2-P, isosafrole and piperonal made up less than 4 per 
cent of seizures.130 Safrole is produced mainly from the sassafras plants and according to a study in South-
East Asia, the plant is found largely in China, Myanmar and Cambodia.131 In East and South-East Asia, 
more than 360 plants containing essential oils rich in safrole were identified most of which were of the 
Cinnamomum species.132 Other plant species, rich in safrole, are also found in the Americas. Given that the 
cultivation of safrole is largely unregulated, there remain high risks of diversion for illicit manufacture.
With regards to licit trade, piperonal has emerged as the main “ecstasy” precursor chemical exported 
worldwide. Between 1998 and 2000, licit global piperonal exports increased significantly, while exports 
of other “ecstasy” precursor chemicals, such as isosafrole, declined, after having reached a peak in 1998.133 
Worldwide, 38 Governments reported exports of “ecstasy” precursor chemicals between 2007 and 2012 with 
a total annual value of US$ 42 million.134 Over the same period, the largest exporters of “ecstasy” precursor 
chemicals were China at 56 per cent, followed by Hong Kong (China) at 21 per cent.135 The largest importers 
over this period were Hong Kong (China) at 18 per cent, followed by the United States at 17 per cent.136
While 3,4-MDP-2-P has little licit use and is an internationally controlled precursor, safrole is used in 
the manufacture of pesticides, insecticides and fragrances, and as an antiseptic to treat infestations, as well 
as an additive in products such as root beer, sassafras tea or pinga com sassafras (Brazil).137 Isosafrole and 
piperonal are also widely used in the chemical and pharmaceutical industries.138 Between November 2012 
and November 2013, INCB was informed of 50 shipments of safrole, including in the form of safrole-rich 
oils, with a total volume of about 5,800 litres, via the Pre-Export Notification Online (PEN Online) system. 
The annual licit global requirements of safrole are estimated at 3,500 tons.139 Extensive licit trade of safrole 
challenges the monitoring of its diversion for illicit ecstasy manufacture.
precursor seizures reported in 2011 is primarily attrib-
utable to the surge of safrole seizures reported in Thai-
land, from where there have been no reports of “ecstasy” 
manufacture to UNODC. Of the ecstasy chemical pre-
cursor seizures reported in 2011 and 2012, consisting 
mostly of safrole and some 3,4-MDP-2-P, 70 per cent 
were reported in Thailand, 12 per cent in Malaysia, 9 
per cent each in Australia and Cambodia, and less than 
1 per cent were reported in China, New Zealand and 
the Philippines.
The large amount of ecstasy chemical precursors 
recently seized in the region might indicate the potential 
to manufacture considerable amounts of ecstasy. Based 
upon the commonly used MDMA manufacturing 
methods as provided by the International Narcotics 
Control Board (INCB), the total of about 66,000 
litres of safrole and 3,4-MDP-2-P seized in the region 
in 2011 and 2012 would have been sufficient to 
potentially manufacture about 44 tons of ecstasy. This 
amount far exceeds the total ecstasy seized worldwide 
in both 2011 and 2012, which amounted to 9 tons.
Although the ecstasy precursor chemicals seized in 
East and South-East Asia and Oceania may have been 
intended for the use of domestic manufacture, reports 
show that large amounts are also being trafficked from 
this region to other parts of the world. For instance, 
between November 2012 and November 2013, the 
Netherlands had reported 3 safrole seizures, two of 
which occurred at the port of Rotterdam, involving 
12,000 litres in a shipment mislabelled as palm oil 
130   International Narcotics Control Board (INCB), Precursor and chemicals 
frequently used in the illicit manufacture of  narcotic drugs and psychotropic sub-
stances 2013, Vienna, March 2014.
131  UNODC Regional Centre for East Asia and the Pacific, “Safrole-rich 
essential oils — risk of  illicit use”, Eastern Horizons, Summer-Autumn 
2007, pp. 9-10.
132 United Nations Office on Drugs and Crime (UNODC), Amphetamines 
and Ecstasy: 2008 Global ATS Assessment, Austria, August 2008.
133  For more information see United Nations Office on Drugs and 
Crime (UNODC), World Drug Report 2014, New York, June 2014.
134  United Nations Office on Drugs and Crime (UNODC), World Drug 
Report 2014, New York, June 2014.
135  United Nations Office on Drugs and Crime (UNODC), World Drug 
Report 2014, New York, June 2014.
136  United Nations Office on Drugs and Crime (UNODC), World Drug 
Report 2014, New York, June 2014.
137  United Nations Office on Drugs and Crime (UNODC), World Drug 
Report 2014, New York, June 2014.
138  United Nations Office on Drugs and Crime (UNODC), 2014 Global 
Synthetic Drugs Assessment: Amphetamine-type stimulants and new psychoactive 
substances, Vienna, May 2014.
139  United Nations Office on Drugs and Crime (UNODC), Amphetamines 
and Ecstasy: 2008 Global ATS Assessment, Austria, August 2008.
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from Thailand and 1,800 litres in a shipment from 
Cambodia, while another 25 litres were seized in a 
shipment sent via courier service from Indonesia.140 
Over the same period, 1,000 litres of 3,4-MDP-2-P 
originating in China and heading for the Netherlands 
was seized whilst transiting Koper seaport in Slovenia 
in a container mixed with piperonal.141
Geographic diversification in the supply for 
“ecstasy”
Although ecstasy is manufactured in the region, a 
decreasing number of “ecstasy” trafficking attempts 
from countries in East and South-East Asia and 
Oceania are being intercepted within the region and 
beyond. In 2008, seized “ecstasy” had reportedly 
been trafficked from China to Mongolia and New 
Zealand, from Thailand to the Republic of Korea 
and the Philippines, and from Indonesia to Niger.142 
In contrast, in both 2012 and 2013 there had only 
been one report of “ecstasy” having originated from a 
country in the region and in both years “ecstasy” was 
perceived to have originated from China.143 On the 
whole, the number of countries in East and South-
East Asia and Oceania that were identified as origin or 
departure for “ecstasy” trafficking has decreased from 
4-5 times annually between 2007 and 2010, to 3 times 
in 2011, only once in both 2012 and 2013.
“Ecstasy” has been supplied from countries outside 
the region for some time. Since 2008, Canada and 
the Netherlands have annually been identified as 
countries of origin or departure for “ecstasy” seized in 
the region, by Australia, Hong Kong (China), Japan 
and the Republic of Korea.144 However, the number 
of countries annually identified for “ecstasy” trafficked 
from outside the region to East and South-East Asia 
and Oceania has increased from just 2 in 2009 to 7 in 
2012, most of which are located in Western Europe 
and include France, Germany, the Netherlands and the 
United Kingdom, in addition to Canada, the Islamic 
Republic of Iran and the United States.145
Moreover, there appears to have been a regional 
diversification of “ecstasy” trafficking to the region, 
which up until 2011 had been limited to Western 
Europe and North America, but since 2012 has 
included Western Asia. The number of recipient 
countries for trafficked “ecstasy” has also diversified 
from comprising China, Indonesia, Japan and 
Singapore in 2009 to additionally include Australia, 
Hong Kong (China), the Republic of Korea and New 
Zealand (with the exception of China, which was not 
identified as a destination country for “ecstasy” seized 
Figure 12. The number of times countries in 
East and South-East Asia and Oceania have 
been identified as countries of origin for “ecsta-
sy” seized worldwide, 2007-2013
Source(s): United Na
ons Office on Drugs and Crime (UNODC), 
Annual Report Ques
onnaire 2007-2013.
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140  International Narcotics Control Board (INCB), Precursor and chemicals 
frequently used in the illicit manufacture of  narcotic drugs and psychotropic sub-
stances 2013, Vienna, March 2014.
141  International Narcotics Control Board (INCB), Precursor and chemicals 
frequently used in the illicit manufacture of  narcotic drugs and psychotropic sub-
stances 2013, Vienna, March 2014.
142  United Nations Office on Drugs and Crime (UNODC), Annual Re-
port Questionnaire 2008.
143  United Nations Office on Drugs and Crime (UNODC), Annual Re-
port Questionnaire 20012-2013.
144  United Nations Office on Drugs and Crime (UNODC), Annual Re-
port Questionnaire 2008-2012.
145  United Nations Office on Drugs and Crime (UNODC), Annual Re-
port Questionnaire 2008-2012.
Figure 13. The number of countries outside 
East and South-East Asia and Oceania identi-
fied as the origin or departure for “ecstasy” 
seized in East and South-East Asia and Ocean-
ia, 2009-2012
Source(s): United Na
ons Office on Drugs and Crime (UNODC), 
Annual Report Ques
onnaire 2009-2012.
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Map 5: “Ecstasy” flows to countries in East and South-East Asia and Oceania as perceived 
by recipient country, 2009 and 2012*
* Not actual trafficking routes.
Source(s): United Nations Office on Drugs and Crime (UNODC), Annual Report Questionnaire 2009 and 2012.
in 2012 by any country worldwide). Given that the 
exact annual amount of “ecstasy” trafficked from 
outside the region is unknown, this trend does not 
imply that there are increasing amounts of “ecstasy” 
being sourced in East and South-East Asia from other 
countries in the world, but that the interception 
of trafficking attempts from countries outside the 
region has increased. For instance, according to the 
Australian Crime Commission (ACC), the number 
of small quantity MDMA detections along the 
Australian border is on the rise, most of which occur 
in the postal stream and have been trafficked from 
Western European countries, including Germany, the 
Netherlands and the United Kingdom.146
Ongoing gaps and data limitations
 
On the whole, there are indications of increasing activity 
in the regional “ecstasy” market. However, information 
on “ecstasy” prices, purity levels and prevalence rates 
remains scarce and prevents establishing conclusive 
arguments on the “ecstasy” situation in the region. Also, 
there are discrepancies in the data and information 
regarding ecstasy manufacture. The number of 
dismantled laboratories provides an incomplete 
picture, given that the size of the operations are usually 
not known, and yet, large seizures of safrole point to 
a high availability of ecstasy precursor chemicals. The 
emergence of NPS further confuses the analysis of the 
“ecstasy” market. Given that a number of countries 
in the region have reported of NPS sold as “ecstasy” 
146  United Nations Office on Drugs and Crime (UNODC), Annual Re-
port Questionnaire for Australia 2012 and 2013.
on ATS markets, reports of high level “ecstasy” use 
in some countries may be misleading. Furthermore, 
although law enforcement agencies in certain countries 
have reported increased “ecstasy” seizures, many of 
these tablets might have contained NPS with little or 
no MDMA. Therefore, more forensic evidence and 
analysis is needed to distinguish between “ecstasy” 
seizures of varying MDMA content.
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4. The NPS market in East and South-
East Asia and Oceania
and the number of NPS encountered, as well as in the 
patterns of emergence and persistence of NPS. 
As on the global level, the number of NPS reported in 
East and South-East Asia and Oceania, has increased 
significantly, from 34 substances in 2009 to 137 in 
2014 (Nov). The largest increase in terms of newly 
reported NPS was observed between 2010 (52 NPS) 
and 2011 (91 NPS), with major increases within 
the synthetic cannabinoid group and the synthetic 
cathinone group. Indeed, in East and South-East 
Asia and Oceania, most reported NPS belong to 
the synthetic cannabinoid group (42 substances). 
However, synthetic cathinones account for a larger 
share of the total NPS reported in the region at 25 
per cent, than on the global level where synthetic 
cathinones account for only a  15 per cent share of the 
total reported NPS. This may reflect the important 
role of ATS in East and South-East Asia and Oceania, 
the effects of which can be mimicked by synthetic 
cathinones. 
Figure 14. Number of NPS reported in East 
and South-East Asia and Oceania up to 2014 
(Nov)
Source(s): United Na
ons Office on Drugs and Crime (UNODC), 
Early Warning Advisory on new psychoac
ve substances, 2014 
(Nov).
10
34
52
91
114
131
24
18
39
23
17
6
34
52
91
114
131 137
0
50
100
150
2009 2009-
2010
2009-
2011
2009-
2012
2009-
2013
2009-
2014(Nov)
N
um
be
r o
f r
ep
or
te
d 
N
PS
NPS reported in previous 
years - East and South-East 
Asia and Oceania
NPS reported for the first 

me - East and South-East 
Asia and Oceania
147  New psychoactive substances are substances of  abuse, that are not 
controlled by the 1961 Single Convention on Narcotic Drugs or the 
1971 Convention on Psychotropic Substances, but which may pose a 
public health threat. In this context, the term ‘new’ does not necessar-
ily refer to newly developed substances,  but to substances that have 
been recently become available.
148  For the purpose of  this report, NPS includes ketamine which differs 
from other NPS in that is widely used in human and veterinary medi-
cine, while most NPS have little or no history of  medical use. 
149  So-called mimetics are substances that are chemically different but 
mimic the pharmacological effects of  a particular substance, notably 
by acting on the same receptors of  the brain; See United Nations 
Office on Drugs and Crime (UNODC), World Drug Report 2013, New 
York, May 2013.
150  The 9 substance groups identified are: aminoindanes, ketamine and 
phencyclidine-type substances, phenethylamines, piperazines, plant-
based substances, synthetic cannabinoids, synthetic cathinones, trypt-
amines, and other substances (which refers to NPS that do not fit into 
the aforementioned groups).
151  (1-Pentyl-1H-indol-3-yl)-1-naphthalenyl-methanone (JWH-018) is a 
synthetic cannabinoid not under international control at the time of  
drafting this report.
The amphetamine-type stimulants (ATS) market has 
long been characterized by a variety of substances. In 
recent years, a number of new psychoactive substances 
(NPS)147 have rapidly emerged on this market.148 
By November 2014, close to one hundred Member 
States and territories reported the emergence of NPS 
to UNODC. Many NPS share similar effects and 
profiles of substances under international control 
that they are designed to mimic.149 So far, 9 NPS 
substance groups have been identified.150 For instance, 
synthetic cannabinoids (e.g. JWH-018151) are 
mimetics of THC (delta-9-Tetrahydrocannabinol), 
the main psychoactive substance of cannabis. Several 
NPS mimicking the effects of ATS belong to the 
synthetic cathinone group which have stimulant and 
empathogenic properties, and the phenethylamine 
group which includes substances that can induce 
stimulant and hallucinogenic effects. 
Since 2009 until the writing of this report, over 500 
NPS have been reported to UNODC worldwide. Data 
reported to the UNODC Early Warning Advisory on 
NPS (EWA) indicate that the NPS market is very 
dynamic and that a number of NPS may be transient. 
There are notable variations in the substance groups 
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What is the diversity of available NPS in the 
region?
Within East and South-East Asia and Oceania, coun-
tries reported a large diversity of NPS substance groups, 
as well as varied emergence patterns and persistence 
trends. On the whole, the largest number of NPS in 
the region between 2008 and 2014 was reported by 
Australia (73 substances), followed by New Zealand 
(49 substances), Singapore (37 substances), Japan (31 
substances) and Indonesia (29 substances). 
Aside from these countries, other countries in the region 
have also reported NPS, but of a much less diverse range. 
For instance, Cambodia, Macau (China), and Viet Nam 
have only  reported the emergence of ketamine. This 
could relate to the many technical challenges in identi-
fying NPS faced by forensic laboratories in the region. 
To date, the Lao People’s Democratic Republic (PDR) 
has not reported the emergence of NPS to UNODC. 
The NPS market in the region is characterized by a 
large number of synthetic cannabinoids, synthetic 
cathinones and phenethylamines. While synthetic 
cathinones became established on the market as far 
back as 2009, with 34 substances reported by 2014 
(Nov), synthetic cannabinoids only began to play a 
major role on the market from 2011 onwards. Indeed, 
the largest increase of NPS in the region has been ob-
served within the synthetic cannabinoid group, rising 
from only 2 substances reported in 2009 to a total of 
42 substances reported by 2014 (Nov). 
Of the 137 NPS reported between 2008 and 2014 
(Nov), 72 substances were reported in two or more years 
but 65152 substances were reported only once, which 
suggests that a sizeable proportion of NPS may be tran-
sient and have not established a permanent presence on 
the drug market. Most of the substances that, according 
to country reports, are no longer available on the mar-
ket153 belong to the synthetic cannabinoid and synthetic 
Figure 15. Global and regional percentages of NPS by substance group, 2008-2014 (Nov)
Source(s): United Na
ons Office on Drugs and Crime (UNODC), Early Warning Advisory on new psychoac
ve substances, 2014 (Nov)
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Figure 16. Number of NPS reported in East 
and South-East Asia and Oceania, by country, 
up to 2014 (Nov)
Source(s): United Na
ons Office on Drugs and Crime (UNODC),  
Early Warning Advisory on new psychoac
ve substances, 2014 
(Nov)
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152  Of  the 65 NPS, 6 NPS were reported for the first time in 2014. 
153  Substances included in this group have only been reported in a single year 
between 2008 to 2014 and no further reports of  these substances being 
observed on the market have been submitted by countries/territories in 
the region.
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cathinone groups. Some stability has been observed in 
the cases of 33 NPS that have been reported of in at 
least 3 consecutive years. In the region, there appears 
to be an established presence of some NPS, of which 
8 substances had been annually reported since 2009. 
These substances include BZP154, DMA155, JWH-018, 
ketamine, kratom, mephedrone156, methylone157 and 
TFMPP158. The substance that had been reported 
by the most number of countries/territories was ket-
amine (15 countries), followed by BZP (9 countries) 
and TFMPP (8 countries).
A large market for ketamine in East and South-
East Asia and Oceania
As a substance that has a closely related chemical struc-
ture to the internationally controlled substance phen-
cyclidine, listed in Schedule II of the 1971 Convention 
on Psychotropic Substances, ketamine was synthesized 
as an anaesthetic and marketed as a medical alterna-
tive to phencyclidine in the early 1970s. Although it 
is a widely used anaesthetic in veterinary and human 
medicine, it is also used throughout the region for 
recreational purposes and non-medical use dates back 
to the 1980s and 1990s.159 Chronic ketamine use can 
induce several health issues including high blood pres-
sure, abdominal pain, lower urinary tract symptoms, 
disorientation, impaired vision and confusion.160
Table 1: NPS most frequently reported by countries/territories, 2008 -2014 (Nov)
Substance name Number of countries/ territories 
Ketamine 15
1-Benzylpiperazine (BZP) 9
1-(3-Trifluoromethylphenyl)piperazine (TFMPP) 8
Mephedrone (4-MMC) 7
Catha edulis (khat) 7
Source(s): United Nations Office on Drugs and Crime (UNODC), Early Warning Advisory on new psychoactive substances, 2014 (Nov)
There are indications that non-medical use of ketamine 
is increasing in some countries. Although the annual 
prevalence of ketamine use in Hong Kong (China), 
declined from 0.05 per cent in 2012 to 0.04 per cent 
in 2013, prevalence rates remained at a higher level 
than for ATS use at 0.03 per cent. In 2013, ketamine 
users continued to account for almost 28 per cent of 
all drug users and between 2009 to 2013, ketamine 
was identified as the second most used drug, according 
to expert perception.161 In 2012 and 2013, experts 
perceived an increase in ketamine use in Brunei 
Darussalam, China and Macau (China).162 Among 
people held in prison in Macau (China), annual use 
of ketamine in 2013 stood at almost 27 per cent, 
signifying an increase from 18 per cent in 2012.163 
An increasing number of ketamine-related treatment 
admissions have been registered since 2008, rising from 
21 admissions that year to 158 admissions in 2013. 
The number of people treated for ketamine use in 
Singapore almost doubled to 29 people between 2011 
and 2013, which is comparable to Thailand where the 
number of people treated for ketamine use rose  to 31 
in 2013.164 Over the last few years, Australia and New 
Zealand reported stable ketamine use, at an annual 
prevalence rate of 0.21 per cent use in 2010165 and 0.3 
per cent use in 2007 among the general population166 
respectively.167
154  1-Benzylpiperazine (BZP) is a piperazines not under international con-
trol at the time of  drafting this report.
155  N,N-Dimethylamphetamine (DMA) is a phenethylamine not under 
international control.
156  4-Methylmethcathinone (4-MMC or mephedrone) is a synthetic cathi-
none not under international control at the time of  drafting this report.
157  3,4-Methylenedioxy-N-methcathinone (bk-MDMA or methylone) is a 
synthetic cathinone not under international control at the time of  draft-
ing this report.
158  1-(3-Trifluoromethylphenyl)piperazine (TFMPP) is a piperazine not 
under international control.
159  European Monitoring Center for Drugs and Drug Addiction (EMCD-
DA), ‘Report on the risk assessment of  ketamine in the framework of  
the joint action on new synthetic drugs’, Belgium, 2002.
160  United Christian Hospital (2010), Emergency department presentation 
of  ketamine abusers in Hong Kong: a review of  233 cases, Hong Kong 
Medical Journal 16:6-11; United Nations Office on Drugs and Crime 
(UNODC), The challenge of  new psychoactive substances, Global Synthetics 
Monitoring: Analyses, Reporting and Trends (SMART) Programme, Vi-
enna, March 2013; T. Okon, (2007) “Ketamine: an introduction for the 
pain and palliative medicine physician”, Pain Physician, 10 (3): 493-500.
161  United Nations Office on Drugs and Crime (UNODC), Annual Re-
port Questionnaire for Hong Kong (China), 2009 – 2013.
162  United Nations Office on Drugs and Crime (UNODC), Annual Re-
port Questionnaire for Brunei Darussalam, China and Macau (Chi-
na), 2012 and 2013.
163  United Nations Office on Drugs and Crime (UNODC), Annual Re-
port Questionnaire for Macau (China), 2012 and 2013.
164  United Nations Office on Drugs and Crime (UNODC), Annual Re-
port Questionnaire for Singapore and Thailand, 2011-2013.
165  Australian Institute of  Health and Welfare, 2010 National Drug Strategy 
Household Survey Report, Drug Statistics Series No. 25, Canberra, July 
2011.
166  In these use surveys, the term “general population” in Australia refers 
to people aged 15-64 and in New Zealand to people aged 16-64.
167  United Nations Office on Drugs and Crime (UNODC), Annual Re-
port Questionnaire for New Zealand 2010-2013.
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Over the last 6 years, ketamine seizures in the region 
have accounted for a large share of global total ketamine 
seized. Ketamine seizures increased significantly to 
almost 10 tons in 2013, which marks an 85 per cent 
increase from the amount seized in 2012. Ketamine 
continues to be the second most seized substance in 
China at nearly 9.7 tons, after ATS seizures at 18.4 
tons. Hong Kong (China), has also reported a more 
than two-fold increase to about 0.3 tons in 2013 
from the previous year. Ketamine seizure increases 
have also been reported in Australia where 199 seizure 
cases were detected in 2012/13, rising from 59 seizure 
cases in 2011/12.168 Ketamine seizures in other 
countries, such as Malaysia169 and Indonesia170, have 
been comparatively lower and the amounts seized in 
these countries have decreased over the last few years. 
There are indications that a large share of the amount 
of ketamine seized in the region was intended for the 
domestic market.
Between 2008 and 2013, illicit ketamine manufacture 
has been reported by several countries and territories 
in Asia, mostly China and India, as well as Taiwan, 
Province of China, and Hong Kong (China). A total of 
122 ketamine laboratories were dismantled in China 
in 2013171, compared to 81 laboratories in 2012.172 
According to the Chinese authorities, large quantities 
of ketamine were manufactured in  Guangdong, 
China.173 Hong Kong (China), and India both 
reported clandestine ketamine manufacture, having 
each dismantled a clandestine ketamine laboratory in 
2012.174
Several countries in East and South East Asia seized 
ketamine that was perceived to have originated from 
within the region, namely from China and India. 
Between 2009 and 2013, Brunei Darussalam, Hong 
Kong (China), Japan, and Indonesia reported seizures of 
ketamine perceived to have been trafficked from China 
and/or Malaysia.175 Over the same period, countries in 
Western Europe and North America seized ketamine 
Figure 17. Ketamine seizures reported in 
selected countries in East and South-East Asia 
and total global seizures, 2008-2013 
Source(s): United Na
ons Office on Drugs and Crime (UNODC), 
Annual Report Ques
onnaire (ARQ) 2008-2013. China data for 
2012:Na
onal Narco
cs Control Commission of China (NNCC).
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Map 6: Cumulative ketamine seizures 
reported in East and South-East Asia and 
Oceania, 2008-2013
 
 
Source(s): United Nations Office on Drugs and Crime (UNODC), Annual 
Report Questionnaire (ARQ) and Early Warning Advisory on new 
psychoactive substances, 2014 (Nov). * Amount is not specified - Drug 
Abuse Information Network for Asia and the Pacific (DAINAP).
0.1-10
10.1-100
100.1-1,000
1,001-5,000
5,001-20,000
≥ 20,000
Seizure (kg)
The boundaries and names shown and the designations used on this map 
do not imply official endorsement or acceptance by the United Nations.
168  Australia Crime Commission, 2012-13 Illicit Drug Data Report,  Data 
from: Australian Customs Border and Protection Service, 2014.
169  United Nations Office on Drugs and Crime (UNODC), Annual 
Report Questionnaire for Malaysia, 2009; Drug Abuse Information 
Network for Asia and the Pacific (DAINAP), 2012.
170  United Nations Office on Drugs and Crime (UNODC), Annual Re-
port Questionnaire for Indonesia,  2010; Drug Abuse Information 
Network for Asia and the Pacific (DAINAP), 2013.
171  United Nations Office on Drugs and Crime (UNODC), NPS ques-
tionnaire 2014 for China.
172  United Nations Office on Drugs and Crime (UNODC), Annual Re-
port Questionnaire for China, 2012-2013.
173  United Nations Office on Drugs and Crime (UNODC), NPS ques-
tionnaire 2014 for China.
174  United Nations Office on Drugs and Crime (UNODC), Annual Re-
port Questionnaire for Hong Kong (China) and India, 2012.
175  United Nations Office on Drugs and Crime (UNODC), Annual Re-
port Questionnaire for Hong Kong (China),  Japan,  Indonesia and 
Brunei Darussalam,  2009-2013.
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that was reportedly trafficked from China.176 Ketamine 
seizures reported by Hong Kong(China) and Japan 
between 2008 and 2012 were perceived to have been 
trafficked from Taiwan Province of China.177 Some 
countries in the region, such as Brunei Darussalam, 
Hong Kong (China) and Thailand seized ketamine 
between 2009 and 2013 that was perceived to have 
been intended for onward trafficking to Malaysia.178 
With regards to inter-regional ketamine trafficking, 
Brunei Darussalam, Hong Kong (China), Indonesia, 
Malaysia, Myanmar, Taiwan Province of China and 
Thailand seized ketamine perceived to have originated 
from India.179 According to the Australian authorities, 
more than half of the ketamine seized in 2013 was per-
ceived to have been trafficked from the United King-
dom and in 2012, some of which had originated from 
the Netherlands and Peru. The Republic of Korea re-
ported seized ketamine that was perceived to have been 
trafficked to the country via the United States.180
Seizure reports, use data and dismantled laboratories 
indicate a large market for ketamine in the region. 
Ketamine seizure information also indicates exten-
sive inter-regional and intra-regional trafficking, with 
176  United Nations Office on Drugs and Crime (UNODC), Annual Re-
port Questionnaire for Belgium and Canada, 2009-2012.
177  United Nations Office on Drugs and Crime (UNODC), Annual Re-
port Questionnaire for Hong Kong (China)  and Japan, 2008-2012.
178  United Nations Office on Drugs and Crime (UNODC), Annual Re-
port Questionnaire for Brunei Darussalam; Hong Kong (China) and 
Thailand, 2009-2013.
179  United Nations Office on Drugs and Crime (UNODC), Annual Re-
port Questionnaire for Brunei Darussalam; Hong Kong (China), In-
dia, Indonesia, Myanmar and Thailand , 2009-2013.
180  United Nations Office on Drugs and Crime (UNODC), NPS ques-
tionnaire 2014 for the Republic of  Korea.
Map 7: Ketamine flows as perceived by countries of origin and recipient countries, 2009 
-2013*
* Not actual trafficking routes.
Source(s): United Nations Office on Drugs and Crime (UNODC),  Annual Report Questionnaire (ARQ) 2009-2013;  United Nations Office on Drugs 
and Crime (UNODC), NPS questionnaire 2014 for the Republic of Korea; Australia Crime Commission, 2012-13 Illicit Drug Data Report, 2014.
Note: The origins of the flow arrows do not necessarily indicate the source/manufacture of ketamine. These arrows represent the flows as perceived 
by recipient countries. Dashed lines represent undetermined boundaries. Dotted line represents approximately the Line of Control in Jammu and 
Kashmir agreed upon by India and Pakistan. The final status of Jammu and Kashmir has not yet been agreed upon by the parties.
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ketamine from the East and South-East Asian region 
being mostly trafficked to Western Europe and North 
America.
A growing market for plant-based substances
Traditionally, kratom (Mitragyna speciosa) has been 
used in Malaysia and Thailand as a substitute for opium, 
and in traditional medicine, due to its “morphine-like” 
effects. Khat (Catha edulis) is a plant-based NPS, which 
has only recently emerged in East and South-East Asia 
and Oceania. Khat contains the amphetamine-type 
stimulant, cathinone, and has been traditionally used 
in East Africa and parts of the Middle East. Over the 
last 6 years, khat use has emerged in several other 
regions including Europe and North America.
Thailand continues to report the largest amounts of 
kratom seizures in the region, and there are reports of 
extensive illicit kratom cultivation and use particularly 
in the southern parts of the country. In 2013, kratom 
seizures in Thailand increased by 57 per cent to 45.5 
tons from the previous year, and in Malaysia kratom 
seizures had risen by more than 74 per cent from the 
previous year to 9.1 tons in 2013. Malaysia continues 
to report illicit kratom cultivation in the country. 
Myanmar also annually reported significant amounts 
of kratom seizures181, and law enforcement authorities 
in Myanmar have eradicated illicit kratom cultivation 
sites in the Tanintharyi Divison in 2013 and 2014.182 
Kratom seizures have also been reported in New 
Zealand, Indonesia and the Republic of Korea.183
In Thailand, treatment admissions for kratom use in-
creased significantly in 2012 to about 11,600 admis-
sions, signifying a four-fold increase from 2011, and 
remained at a relatively high level in 2013 at almost 
10,000 admissions.184 However, treatment admis-
sions for kratom use only accounted for 3.2 per cent 
of all drug use treatment admissions in the country in 
2013.185 Malaysia and Myanmar reported that kratom 
was one of the most commonly used NPS over the past 
years.186
Khat has more recently emerged in some countries 
in East and South-East Asia and Oceania, including 
Australia, China, Hong Kong (China), Indonesia, 
Japan, Malaysia, New Zealand, Thailand and Viet 
Nam. Between 2008 and 2013, the largest amounts 
of annual khat seizures were reported by China and 
Hong Kong (China). Since 2008, when khat seizures 
were first reported by New Zealand, khat seizures 
continue to be reported annually. Indonesia was the 
first country to report of khat cultivation in the region 
in 2013, when the Indonesian National Narcotics 
Board (BNN) discovered a 7 hectare khat plantation 
in Cisarua of Bogor in West Java.187 
A complex picture of intra- and inter-regional khat 
trafficking has emerged in recent years. Khat has been 
perceived to have been trafficked within the region 
e.g. shipments transiting China and Australia towards 
New Zealand,188 as well as being perceived to have been 
trafficked from East and South-East Asia and Oceania 
to other regions worldwide. The Vietnamese authorities 
reported to have seized 5.8 kg of khat in 2012, that was 
perceived to have been destined for the United States189. 
In that same year, the United States reported that a 
181  Central Committee for Drug Abuse Control (CCDAC), “Myanmar 
country report”, presented at the Global SMART Programme Regional 
meeting, Yangon, Myanmar, 20-21 August 2014.
182  Central Committee for Drug Abuse Control (CCDAC), “Myanmar 
country report”, presented at the Global SMART Programme Regional 
meeting, Yangon, Myanmar, 20-21 August 2014.
183  United Nations Office on Drugs and Crime (UNODC), Early Warning 
Advisory on new psychoactive substances, 2014 (Nov).
184  Drug Abuse Information Network for Asia and the Pacific (DAINAP).
185  Drug Abuse Information Network for Asia and the Pacific (DAINAP).
186  Drug Abuse Information Network for Asia and the Pacific (DAINAP).
187  “Comparison Analysis of  Red and Green Khat Leaves (Fresh, Dried 
and After Two Months Frozen”, Drugs Testing Laboratory National 
Narcotics Board Republic of  Indonesia, April 2013.
188  United Nations Office on Drugs and Crime (UNODC), Individual 
Drug Seizures (IDS) for New Zealand,  2010-2013.
189  General Department of  Vietnam Customs (GDVC), ‘Drug Traffick-
ing in Viet Nam’, presented at the World Customs Organization Re-
gional Intelligence Liaison Office for Asia and the Pacific Regional 
Seminar for Information Exchange to Fight against Drug Trafficking, 
Seoul, 16-18 April 2013.
Table 2: Kratom seizures (kg) of selected countries, 2008-2013
Country 2008 2009 2010 2011 2012 2013
Malaysia 1,441.8* 2,813.6* 24,994.0 3,067* 5,237.7* 9,101.5*
Myanmar 308.5 597.5* 375 969.5* 330.2* 219*
Thailand** ● 29,917.8* 44,206.2* 32,913.6* 28,978.4* 45,513.2*
Republic of Korea ● ● ● ● ● 0.3
Source(s): United Nations Office on Drugs and Crime (UNODC),  Annual Report Questionnaire (ARQ); *Drug Abuse Information 
Network for Asia and the Pacific (DAINAP); ** Combined seizures of kratom leaves and kratom liquid.
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large share of khat seizures were perceived to have been 
trafficked via China and Hong Kong (China).190 There 
have also been reports of khat accessing markets in 
East and South-East Asia and Oceania from Africa and 
South Asia. According to law enforcement authorities 
in Hong Kong(China), khat seized in 2013 was 
perceived to have been trafficked from Ethiopia and 
India and intended for onward trafficking  to China.191 
Some khat seizures reported in New Zealand were also 
perceived to have originated from North America and 
Western Europe.192
An emerging market for synthetic cannabi-
noids and synthetic cathinones
Over the last few years, an increasing number and 
availability of synthetic cannabinoids and synthetic 
cathinones, has been reported in East and South-East 
Asia and Oceania, in countries such as Australia, China, 
Hong Kong (China), Indonesia, Japan, Malaysia and 
New Zealand. 
A large number of synthetic cannabinoids has emerged 
in Singapore (17 substances), Japan (16 substances), 
Australia (14 substances) and New Zealand (13 
substances) by November 2014.193 The Republic of 
Korea reported that synthetic cannabinoid trafficking 
to the country has substantially increased during the 
last few years, with seizures annually reported since 
2009 and a total of 1.8 kg of synthetic cannabinoids 
seized in 2013. Other countries such as Australia, New 
Zealand and Singapore have also reported of synthetic 
cannabinoid seizures cases these last few years. Data 
on NPS use remains scarce in many countries of 
the region. The New Zealand Arrestee Drug Use 
Monitoring 2013 Report found that among detainees 
who had tried a drug for the first time, 9 per cent had 
used synthetic cannabinoids for the first time in 2012, 
which increased to 46 per cent in 2013, while 7 per 
cent of detainees had used synthetic cannabinoids 
prior to their arrest in 2013.194 Although the findings 
of this survey account for a sub-population and are not 
representative for the general population, these figures 
might provide an indication of the growing importance 
of synthetic cannabinoids in recent years. 
With regard to synthetic cathinones, the largest 
number of substances of this group was reported by 
Australia (23 substances) followed by New Zealand (13 
substances), Singapore (10 substances) and Indonesia 
(8 substances).195 In 2013, New Zealand Customs 
seized a number of NPS imported in powder form, 
presumably intended to be pressed into tablets.196 New 
Zealand and Australian law enforcement authorities 
identified mephedrone as the seventh and eighth 
most used drug, respectively in 2013.197 According 
to Australian law enforcement authorities, synthetic 
cathinones in 2012-2013 accounted for the majority 
of analysed border seizures by number,198 most of 
which were detected in air cargo parcels and the 
international mail stream. In the Republic of Korea, 
MDPV was observed to be the most frequently 
detected substance of the synthetic cathinone group, 
accounting for a 29 per cent share in 2012.199 Other 
190  United Nations Office on Drugs and Crime (UNODC), Annual Re-
port Questionnaire for the United States, 2008-2012.
191  United Nations Office on Drugs and Crime (UNODC), Annual Re-
port Questionnaire for Hong Kong (China), 2013.
192  United Nations Office on Drugs and Crime (UNODC), Individual 
Drug Seizures for New Zealand, 2010-2013.
193  United Nations Office on Drugs and Crime (UNODC), Early Warn-
ing Advisory on NPS, 2014 (Nov).
194  SHORE and Whariki Research Centre and Massey University, New Zea-
land Arrestee Drug Use Monitoring 2013 Report, May 2014.
195  United Nations Office on Drugs and Crime (UNODC), Early Warning 
Advisory on NPS, 2014 (Nov).
196  National Drug Intelligence Bureau (NDIB), ‘Illicit Drug Assessment 
2012’, Wellington, 2013.
197  United Nations Office on Drugs and Crime (UNODC), Annual Re-
port Questionnaire for New Zealand and Australia, 2013.
198  Australian Crime Commission (ACC), Illicit Drug Data Report 2012-13, 
Canberra, April 2014.
199  Korea Customs Service, “Designer drug situation and activities of  
customs laboratories in Korea”, presented at the Group of  European 
Customs Laboratories workshop on designer drugs, Berlin, 27-28 Sep-
tember 2012.
Table 3: Khat seizures (kg) of selected countries/territories, 2008-2013
Country 2008 2009 2010 2011 2012 2013
Australia ● 89.7 ● ● ● ●
China 5271.1 ● ● ● ● ●
New Zealand 145.9* 136.9 84.7* 74.4* 52.0* 58.7*
Thailand ● ● ● ● ● 130.0**
Hong Kong (China) ● ● ● ● 1,096.8 313.7
Source(s): United Nations Office on Drugs and Crime (UNODC), Annual Report Questionnaire (ARQ); * UNODC Individual Drug Seizures; ** Drug 
Abuse Information Network for Asia and the Pacific (DAINAP)
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detected synthetic cathinones include mephedrone and 
flephedrone. More recently, synthetic cathinones have 
emerged on the illicit drug market in Indonesia (such 
as methylone)200, Thailand (such as dimethylone and 
ethylone)201 and Viet Nam (such as mephedrone).202
There are some reports of synthetic cannabinoids and 
synthetic cathinones as well as other NPS identified 
in East and South-East Asia and Oceania being 
manufactured within the region. In 2013, China 
reported to have dismantled a clandestine laboratory 
that was primarily synthesizing 4-MEC and methylone 
as well as JWH-018.203 According to Chinese law 
enforcement authorities, most NPS manufactured 
in the country were not intended for the domestic 
market but for trafficking to other countries, mainly 
by express mail and through international courier 
services. In 2012, Belarus204 and in 2013, Australia, the 
United States and the European Union were among the 
perceived destinations for NPS manufactured in China. 
According to the United States Drug Enforcement 
Administration (DEA), a 1,500 kg seizure report of 
synthetic cannabinoids and synthetic cathinones in 
June 2013, manufactured in India and China was 
perceived to have been intended for the United States 
and Australian drug market.205  Trafficking of NPS 
from China and India was reported by several European 
countries, including Bulgaria206, Hungary, Latvia, Malta 
and Poland between 2010 to 2013.207 Other European 
countries, such as Italy, reported synthetic cannabinoid 
seizures that were perceived to have been trafficked 
from New Zealand in 2011.208
Although most NPS seized in Japan were trafficked into 
the country as blended (ready-for-use) products, some 
smaller quantities of NPS were blended domestically.209 
In November 2013, Japan Police charged a company 
that had been manufacturing and selling NPS, arrested 
5 people in connection with this case and seized more 
than 100 kg of the synthetic cathinone alpha-PVP210. 
The precursor chemicals used to manufacture the NPS 
were believed to have been imported from overseas.211 
In 2013, there have been reports by the Republic of 
Korea, of synthetic cannabinoids that were perceived 
to have been trafficked from Japan into the country.212
There have also been reports of synthetic cannabinoids 
perceived to have been trafficked from North America 
and Western Europe to East and South-East Asia.213 
The Republic of Korea reported that shipments 
containing JWH-018, JWH-210, AM-2201 in 2013 
were perceived to have been trafficked from the 
United States, the United Kingdom, Netherlands and 
Spain.214 In 2013, 1.4 kg of synthetic cannabinoids 
seized in the Republic of Korea, were perceived to 
have been trafficked from the United States.
NPS sold as such and under the name of con-
trolled drugs
With many NPS sharing similar effects and profiles 
of substances under international control, they may 
be used to substitute or complement other drugs. 
According to the Australian Crime Commission, 
over the last years, a number of NPS have been used 
as substitutes for ATS. In a study conducted among 
frequent users of “ecstasy” and other stimulants in 
Australia in 2014, 36 per cent had also recently used 
an NPS (excluding synthetic cannabinoids).215
In recent years, countries in East and South-East Asia 
and Oceania have reported NPS that had been sold as 
“ecstasy”. In these cases, a large share of the tablets sold 
as “ecstasy” contained substances other than MDMA, 
such as ketamine, piperazines, synthetic cannabinoids, 
synthetic cathinones and phenethylamines. In East 
and South-East Asia these substances have been found 
200  Drug Abuse Information Network for Asia and the Pacific (DAINAP).
201  United Nations Office on Drugs and Crime (UNODC), Early Warning 
Advisory on NPS, 2014 (Nov).
202  Standing Office on Drugs and Crime (SODC), Ministry of  Public Se-
curity, “Viet Nam country report”, presented at the Global SMART 
Programme regional meeting, Yangon, Myanmar 20-21 August 2014.
203  United Nations Office on Drugs and Crime (UNODC), NPS question-
naire 2014 for China.
204  United Nations Office on Drugs and Crime (UNODC), NPS question-
naire 2014 for China and United Nations Office on Drugs and Crime 
(UNODC), Annual Report Questionnaire for Belarus, 2012.
205  Australia Crime Commission (ACC), 2012-13 Illicit Drug Data Report, 
2014.
206  Seizures from China included the synthetic cannabinoids AM-2201, 
AB-Pinaca and UR-144.
207  United Nations Office on Drugs and Crime (UNODC), Annual Re-
port Questionnaire for Hungary, Latvia, Malta and Poland, 2010-2013.
208  United Nations Office on Drugs and Crime (UNODC), Annual Re-
port Questionnaire for Italy, 2011.
209  United Nations Office on Drugs and Crime (UNODC), NPS ques-
tionnaire 2014 for Japan.
210  alpha-Pyrrolidinopentiophenone (alpha–PVP) is a synthetic cathinone 
not under international control.
211  A presentation by the International Safety and Security Cooperation 
Division, Ministry of  Foreign Affairs, August 2014.
212  United Nations Office on Drugs and Crime (UNODC), NPS ques-
tionnaire 2014 for the Republic of  Korea, 2013.
213  United Nations Office on Drugs and Crime (UNODC), NPS ques-
tionnaire 2014 for the Republic of  Korea, 2013.
214  United Nations Office on Drugs and Crime (UNODC), NPS ques-
tionnaire 2014 for the Republic of  Korea, 2013.
215  University of  New South Wales, National Drug and Alcohol Re-
search Centre, “Australian drug trends 2014: Findings from the Ec-
stasy and Related Drugs Reporting System” Drug Trends Conference 
hand-out,  2014.
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Map 8: Countries reporting the emergence 
of synthetic cannabinoids and synthetic 
cathinones, 2009-2014 (Nov)
Source(s): United Nations Office on Drugs and Crime (UNODC), Early 
Warning Advisory on new psychoactive substances, 2014 (Nov)
The boundaries and names shown and the designations used on this map 
do not imply official endorsement or acceptance by the United Nations.
in “ecstasy” tablets or in preparation form in Austra-
lia, Brunei Darussalam, China, Hong Kong (China), 
Indonesia, Japan, Macau (China), Malaysia, New Zea-
land, the Philippines, the Republic of Korea, Singa-
pore, Thailand and Viet Nam.216
In New Zealand, blotter paper seizures, which are a 
typical form of presentation for LSD, a hallucinogen 
under international control, increased from 1,290 
units in 2012 to almost 19,000 dose units in 2013. 
According to New Zealand law enforcement authorities, 
many of the largest quantities of blotter paper units 
seized in 2012 and 2013 were identified or suspected 
to contain NPS belonging to the NBOMe-series such 
as 25B-NBOMe, 25C-NBOMe and 25I-NBOMe 
rather than LSD, and the trafficking of NBOMe-series 
substances was reported to have increased in 2012.217 
The majority of such blotter paper seizures were 
perceived to have originated from the Netherlands and 
Germany. Some other countries in the region have also 
found that seized blotter papers contained NBOMe-
series substances instead of LSD.218
Recently, ketamine was also found in tablets sold as 
methamphetamine in the region. Some countries 
had already reported mixtures of ketamine and 
methamphetamine in 2009 and 2010.219 In Indonesia, 
seizures of tablets sold as methamphetamine in 2012 
were reportedly found to contain methamphetamine 
as well as ketamine and other NPS.220 In that 
same year, ketamine and other NPS in addition to 
methamphetamine were found in tablets sold as 
methamphetamine in Australia.221 In 2010, national 
law enforcement authorities in some countries in 
East and South-East Asia seized tablets containing a 
combination of ketamine, BZP and TFMPP, as well 
as tablets containing 2C-B, which is a substance 
under international control, mixed with BZP and 
TFMPP.222 Some tablets analysed in 2014 contained a 
combination of TFMPP and methamphetamine, and 
of methylone and methamphetamine.223
The available data indicates that NPS in the region are 
both sold as such for users who intentionally use them, 
but also marketed under the names of other drugs, with 
or without the purported active substance being pres-
ent, which can involve increased health risks for users.
Which legislative measures have countries ad-
opted to counter NPS?
In recent years, several countries in the region, 
including Australia, Brunei Darussalam, China, 
Indonesia, Japan, New Zealand, the Republic of 
Korea, Singapore and Thailand, have adopted national 
legislative controls related to NPS.224
Most of the countries in the region implemented 
an individual listing system as a legislative control 
of NPS, meaning that each substance is listed 
individually by their chemical name in the respective 
schedules/lists of national drug laws. The emergence of 
BZP in New Zealand in the late 1990s, for example, 
216  For more information, see chapter titled “A growing presence of  ec-
stasy” of  this report.
217  United Nations Office on Drugs and Crime (UNODC), Annual Re-
port Questionnaire for New Zealand, 2012-2013.
218  United Nations Office on Drugs and Crime (UNODC), International 
Collaborative Programme, Official communication with laboratories, 
2013.
219  United Nations Office on Drugs and Crime (UNODC), International 
Collaborative Programme, Official communication with laboratories, 
2009-2010.
220  United Nations Office on Drugs and Crime (UNODC), Annual Re-
port Questionnaire for Indonesia, 2012.
221  United Nations Office on Drugs and Crime (UNODC), Annual Re-
port Questionnaire for Australia, 2012.
222  United Nations Office on Drugs and Crime (UNODC), International 
Collaborative Programme, Official communication with laboratories, 
2010.
223  United Nations Office on Drugs and Crime (UNODC), International 
Collaborative Programme, Official communication with laboratories, 
2014.
224  This list is not exhaustive and meant as an illustration of  recent devel-
opments only.
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triggered the inclusion of BZP and other NPS in the 
Misuse of Drugs Act in 2008. In 2010, Singapore 
added mephedrone, BZP and TFMPP to the Misuse 
of Drugs Act, prohibiting trafficking, manufacture, 
import, export, possession or consumption. In recent 
years, the Government of China, Indonesia, Japan and 
Thailand have also taken measures aimed at restricting 
availability by imposing legislative controls over NPS. 
In China,226 mephedrone was listed as a controlled 
substance in September 2010, followed by several 
JWH-compounds, khat, 2C-I, 2C-H, AM-694, AM-
2201, and MDPV in 2013. To account for the rapid 
emergence of NPS, some countries have introduced 
complementary legislative instruments. This includes 
temporary bans, during which the legislative process 
can be completed and/or a thorough assessment of the 
risks of an NPS can be conducted before any decision 
on permanent control is taken. Such temporary bans 
have been introduced in New Zealand for a number 
of synthetic cannabinoids227 and in the Republic of 
Korea for MDPV in 2011 as well as in Singapore in 
Map 9: Synthetic cathinone and synthetic cannabinoid flows as perceived by recipient 
countries and countries of origin, to and within East and South-East Asia and Oceania, 
2010-2014*
* Not actual trafficking routes.
Source(s): United Nations Office on Drugs and Crime (UNODC), Annual Report Questionnaire 2010-2013, UNODC NPS questionnaire 2014
Note: The origins of the flow arrows do not necessarily indicate the source/manufacture of NPS. These arrows represent the flows as perceived by 
recipient countries and countries of origin225. The boundaries shown on this map do not imply official endorsement or acceptance by the United 
Nations. Dashed lines represent undetermined boundaries. Dotted line represents approximately the Line of Control in Jammu and Kashmir agreed 
upon by India and Pakistan. The final status of Jammu and Kashmir has not yet been agreed upon by the parties.
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New Zealand
Japan
China
Western
and Central
Europe
Republic 
of Korea
Eastern
Europe
North
America
India
The boundaries and names shown and the designations used on this map do not imply official endorsement or acceptance by the United Nations.
225  China reported trafficking of  NPS from China to other countries.
226  Ketamine in preparation form was controlled as a second catego-
ry substance under the Psychoactive Substance list in 2003. It was 
moved into the first category in 2005.
227  Several JWH-compounds in August 2011; JWH-019, JHW-200 and 
AM-1220 in October 2011; AM-2233 in December 2011; DMAA 
AM-1248, AM-2232 and UR-144 in March 2012; CB-13, MAM-2201, 
AKB48 and XLR11 in July 2012; NNE1 in November 2012; STS-135 
and JWH-018 adamantylcarboxamide (also known as 2NE1 or APICA 
in November 2012; EAM-2201 in December 2012, etc. In 2013 other 
synthetic cannabinoids were also placed under temporary control.
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2013 for JWH-compounds, AM-compounds and CP-
compounds.228
The emergence of new analogues of NPS observed 
since 2011 prompted the Japanese Government 
to introduce generic legislation. Japanese generic 
scheduling defines substances by defining positions 
and types of substitutes to their basic structure. 
So far, NPS specific legislation has only been 
implemented in New Zealand with the introduction 
of the Psychoactive Substances Act 2013 (July 2013), 
which regulated the sale, import and manufacture of 
NPS. Initially, some products were granted interim 
approvals and some manufacturers, importers, 
wholesalers and retailers were granted interim licenses 
for NPS. In early 2014, the Psychoactive Substances 
Amendment Act 2014 was passed, which removed all 
interim approvals and licenses from the New Zealand 
market, prohibited the consideration of animal 
testing when assessing products, and introduced a 
moratorium on processing any product approval 
applications or licensing applications until regulations 
came into force.229 In November 2014, regulations 
providing for product approval applications and 
licensing applications for importing, research and 
manufacturing to be processed, came into force. At the 
time of writing this report, no NPS have been granted 
a license in accordance with this Act.
Countries in East and South-East Asia and Oceania 
have also used amendments to regulatory instruments 
such as the Customs Act and Consumer Regulation (in 
Australia) and the Medicine legislation (in Japan). These 
instruments differ from the individual listing system, 
in that their primary intention is not drug control, 
although they may also list substances individually. 
In Australia, a number of NPS, such as mephedrone, 
BZP (in 2010) and a number of CP-compounds (in 
2013) have been placed under import control since 
2010 by amending the Customs (Prohibited Imports) 
Regulations of 1956. In Japan, a new category 
of “designated substances” was introduced in the 
Pharmaceutical Affairs Law in 2007 which foresees a 
three-step process of identification for non‐approved 
or unauthorized pharmaceuticals, which has led to the 
classification of many NPS as designated substances. As 
of September 2014, 1,584 substances were potentially 
controlled under the Japanese Pharmaceutical Affairs 
Law. 
All in all, available information on national legislative 
responses with regards to NPS demonstrates that 
different measures and combinations of approaches are 
being used to respond to the emergence of a growing 
number of NPS in the region whilst taking the country 
specific situation into account. 
228  In May 2014, a number of  NPS under temporary control were reclas-
sified as Class A drugs.
229  Ministry of   Health New Zealand (2014), Background to the Act 
and the regime; Psychoactive Substance Regulatory Authority (Ac-
cessed online at http://psychoactives.health.govt.nz/psychoactive-
substances-act-2013/background-act-and-regime#timeline).
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